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Abstract: Immune cells play critical roles in tumor prevention as well as initiation and progression.
However, immune-resistant cancer cells can evade the immune system and proceed to form tumors.
The normal microenvironment (immune cells, fibroblasts, blood and lymphatic vessels, and interstitial
extracellular matrix (ECM)) maintains tissue homeostasis and prevents tumor initiation. Inflammatory
mediators, reactive oxygen species, cytokines, and chemokines from an altered microenvironment
promote tumor growth. During the last decade, thyroid cancer, the most frequent cancer of the
endocrine system, has emerged as the fifth most incident cancer in the United States (USA), and its
incidence is steadily growing. Inflammation has long been associated with thyroid cancer, raising
critical questions about the role of immune cells in its pathogenesis. A plethora of immune cells
and their mediators are present in the thyroid cancer ecosystem. Monoclonal antibodies (mAbs)
targeting immune checkpoints, such as mAbs anti-cytotoxic T lymphocyte antigen 4 (anti-CTLA-4)
and anti-programmed cell death protein-1/programmed cell death ligand-1 (anti-PD-1/PD-L1), have
revolutionized the treatment of many malignancies, but they induce thyroid dysfunction in up to
10% of patients, presumably by enhancing autoimmunity. Combination strategies involving immune
checkpoint inhibitors (ICIs) with tyrosine kinase (TK) or serine/threonine protein kinase B-raf (BRAF)
inhibitors are showing considerable promise in the treatment of advanced thyroid cancer. This review
illustrates how different immune cells contribute to thyroid cancer development and the rationale for
the antitumor effects of ICIs in combination with BRAF/TK inhibitors.
Keywords: angiogenesis; chemokines; dendritic cells; CXCL8; lymphangiogenesis; macrophages;
mast cells; neutrophils; thyroid cancer; T reg cells
1. Introduction
Thyroid cancer (TC) is the most frequent type of cancer of the endocrine system [1], accounting for
approximately 90% of the endocrine malignancies and for 70% of deaths due to endocrine cancers [2].
During the past two decades, TC incidence increased [3,4]. Risk factors for TC include being female,
having a history of goiter or thyroid nodule, a family history of TC, a low-iodine diet, radiation exposure,
and obesity [5]. TC is three to four times more likely to develop in women, but it is more aggressive
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in men, who present with more advanced disease and have lower survival rates [6]. Differentiated
TC (DTC) includes papillary thyroid carcinoma (PTC) (≈80%) and follicular thyroid carcinoma (FTC)
(≈2%) and medullary thyroid cancer (MTC) (≈4%). Poorly differentiated TC (PDTC) and anaplastic
thyroid carcinoma (ATC) account for approximately 5–10% of all TCs [7], but the majority of deaths
for TC are attributable to this disease [8–10]. Calcitonin-producing parafollicular cells within the
thyroid can give rise to MTC [11]. The association between smoldering inflammation and TC has
long been recognized [12–14]. Indeed, a mixture of immune cells and proinflammatory mediators has
been associated with TC initiation and progression [13]. In this review, we discuss recent findings
investigating how the cells of the innate and adaptive immune system are involved in TC development
and progression. We also discuss the rationale and preliminary results of treatment with monoclonal
antibodies (mAbs), targeting immune checkpoints in patients with aggressive TCs.
2. Molecular and Genetic Factors
Genetic studies of PTCs reported a high frequency of activating somatic alterations of genes
encoding effectors in the mitogen-activated protein kinase (MAPK) signaling pathway, including
point mutations of BRAF (≈60%) and the GTPase RAS family genes (≈13%) [15–17], as well as
fusions involving the REarranged during Transfection (RET) [18] and neutrotrophic receptor tyrosine
kinase 1 (NTRK1) [19]. The most prevalent (≈60%) mutation in PTC is the activating BRAFV600E
mutation [9,17,20]. The second most prevalent genetic event in PTC is paracentric inversions of the long
arm of chromosome 10, causing the fusion of the REarranged during Transfection (RET) intracellular
domain and leading to ligand-independent RET kinase activation [21]. RET fusions are found in
approximately 7% of sporadic PTC [1] and in about 30% of young patients [22]. Mutations in the tumor
suppressor TP53 gene are the most frequent genetic alterations in PDTC [23]. RAS mutations have also
been found in PDTC [24]. Apart from the above-mentioned genetic alterations, several other genes
have been found mutated in FTC, including PI3CA, PTEN, DICER1, EXH1, and SPOP [25,26]. MTC are
commonly associated with RET mutations [21]. In a minority of PTCs, EWSR1 rearrangements have
been identified [27,28].
The TElomerase Reverse Transcriptase (TERT) [29] promoter mutations chr5, 1,295,228 C>T
(C228T) and 1,295,250 C>T (C250T) are present, on average, 0% (benign thyroid tumor), 11.3% (PTC),
17.1% (FTC), 43.2% (PDTC) and 40.1% (ATC) in thyroid tumors, displaying an association with
aggressive types of TC. Coexisting BRAFV600E and TERT promoter mutations have a robust synergistic
impact on the aggressiveness of PTC [30].
ATC is characterized by the accumulation of several different genetic alterations [9]. ATCs
and to a lesser extent PDTC are a challenge for genomic studies due to their extensive infiltration
of macrophages [31,32]. Three recent studies using a next-generation sequencing [33] approach
performed extensive cancer gene exome sequencing in PDTC and ATC [34–36]. Profound genomic
differences between the two advanced forms of the disease have been found. ATCs harbored a
higher number of oncogenic alterations than PDTCs, and the mutations in PDTCs were increased
compared to PTC. BRAFV600E mutations were present in 33% of PDTC and 45% of ATC, whereas
mutations in NRAS, HRAS, or KRAS occurred in 28% and 24% of PDTCs and ATCs, respectively.
TERT promoter mutations, which are important in tumorigenesis, were highly prevalent in ATC
compared to PDTC (73% versus 8%). Mutations in PIK3CA and PTEN were prevalent in ATC
(18% and 53%, respectively). Mutations in EIF1AX were reported in 11% of PDTC and 9% of ATC.
Mutations of genes encoding the phosphoinositide-3-kinase–protein kinase B/Akt-mammalian target
of rapamycin (PI3K-PKB/Akt-mTOR) pathway were more frequent in ATC than PDTC (39% versus
11%). Anaplastic lymphoma kinase (ALK) gene rearrangements have been found in ATC [37] and in
PTC [38]. GLIS3 rearrangements are prevalent in hyalinizing trabecular tumor (HTT), which is a rare
TC with a characteristic trabecular growth pattern and hyalinization [39]. Collectively, these results
have identified several genetic lesions that distinguish PDTC from ATC.
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3. Cytokines
Cytokines, produced by thyroid-infiltrating immune cells and by follicular cells, play a role in the
pathogenesis of autoimmune thyroid disease [14] and contribute to several aspects of TC initiation and
growth [13]. Interleukin (IL)-1 stimulated thyroid cell proliferation and the production of IL-8 [40].
IL-1β serum concentrations were increased in patients with atrophic thyroiditis and decreased in those
with PTC [41].
IL-4 and IL-13 produced by human T helper 2 (Th2) cells, basophils, and T follicular helper cells
(Tfh) [42,43] induce alternative (M2) activation of macrophages and tumor-associated macrophages [44].
Macrophages in TC displayed an M2-like phenotype [45]. The exposure of thyreocytes to ionizing
radiation (IR) caused IL-13 production, which stimulated reactive oxygen species (ROS) increase, and
was presumably responsible for genetic instability and the emergence of neoplastic clones in TC [46].
TC-derived conditioned media (CM) induced the up-regulation of IL-6 in human mast cells [47]
and contributed to epithelial-to-mesenchymal transition (EMT) and stemness, which are features of
TC [48]. Studies comparing levels of circulating IL-6 among TC patients and controls have provided
inconsistent results [49–51].
Tumor-associated macrophages (TAMs) [44] and tumor cells themselves produce IL-10 [52].
IL-10 circulating levels were higher in PTC associated with multinodular goiter (MNG) compared
to MNG alone [53]. Malignant epithelial cells isolated from PTC and ATC [7] produced in vitro IL-4
and IL-10, which increased the expression of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2),
B-cell lymphoma-extra large (Bcl-xL), cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory
protein (cFLIP), and Phosphoprotein enriched in diabetes/Astrocytic phosphoprotein (PED/PEA-15)
in TC cells [54,55]. IL-4 and IL-10 serum concentrations were higher in PTC patients compared to
Hashimoto’s thyroiditis [56]. Moreover, IL-10 expression was correlated with thyroid tumor size and
malignancy [57]. Interestingly, B cells from TC patients produced higher levels of IL-10 compared to
healthy controls [58].
IL-12, a proinflammatory cytokine with antitumor activity [59], was effective against ATC in a
mouse xenograft model [60], and its administration inhibited tumor growth and prolonged survival
by activating both CD8+ T and natural killer (NK) cells in a genetically engineered BRAFV600E mouse
model [61].
IL-17A is produced mainly by human CD4+ Th17 cells and to a lesser extent by CD8+ T cells (Tc17
cells), and was associated with both protumor or antitumor responses [62,63]. The serum concentration
of IL-17 was increased in TC patients compared to thyroid adenoma [64] and correlated with the percent
of circulating Th17 cells [62]. IL17RA polymorphisms negatively correlated with the development of
PTC [65]. The serum levels of IL-17 and the percentage of Th17, Tc17, and T regulatory cells (Tregs)
were increased in patients with DTCs compared to healthy controls [66]. IL-17 and IL-23 expression in
DTCs and MTCs were increased compared to thyroid adenoma, and IL-17 expression was associated
with recurrence and mortality [67].
IL-21 is highly expressed by both Tfh and Th9 cells [68]. In a large cohort of a Chinese population,
IL-21 polymorphism was associated with an increased risk of TC development [69].
IL-24 was induced by RET/PTC3 expression in the thyrocytes of RET/PTC3 transgenic mice, and
it was involved in autocrine growth/survival of RET/PTC3-expressing thyroid cells supporting its
role in early cellular transformation. Its expression decreased in poorly differentiated mouse tumors,
paralleling the loss of RET/PTC3 expression along with tumor progression, thus supporting a role for
IL-24 as a tumor suppressor factor [70].
In a murine model of transgenic BRAF, mouse thyrocytes and TAMs produced TGF-β, which
was responsible for the acquisition of EMT features and the invasiveness of TC cells [71]. In human
PTCs, TGF-β overexpression correlated with tumor invasiveness, regardless of BRAF mutations [72].
The expression of TGF-β in PTC correlated with CD68+ cell infiltration in PTC [73] compared to benign
thyroid nodules [74]. These findings led to suggest that targeting transforming growth factor beta β1
(TGF-β1) could inhibit ATC tumorigenesis [75].
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All three classes of interferons (IFNs), type I (IFN-α/β), type II (IFN-γ), and type III (IFN-λ/s),
induce the apoptosis of tumor cells and modulate cancer immunosurveillance [76]. In TC, type I and
type II IFNs induced the expression of Major Histocompatibility Complex (MHC)-I molecules on
human TC cell lines, thus limiting TC immunoevasion and potentiating TC susceptibility to immune
destruction [77]. IFN-γ inhibited the migration of PTC cells in vitro and induced EMT [78]. Moreover,
IFN-γ inhibited CXCL8 secretion from BRAFV600E mutated thyroid cell lines [79].
4. Chemokines
Chemokines are functionally related small molecules with chemoattractant and cytokine-like
functions that also modulate angiogenesis and lymphangiogenesis [80]. Chemokines can be produced
by TC cells, following the activation of the MAPK pathways by the RET/PTC, RAS, and BRAF oncogenic
drivers [81,82]. Thyroid cells produce a wide spectrum of CXC chemokines (i.e., CXCL1, CXCL8,
CXCL9, CXCL10, and CXCL11) in basal conditions and/or under the influence of specific stimuli [83,84].
In thyroid tissue, recruited T helper 1 (Th1) lymphocytes can enhance IFN-γ and tumor necrosis
factor α (TNF-α) production, which in turn stimulate the chemokine secretion from the thyroid cells,
therefore creating an amplification feedback loop, initiating and perpetuating the autoimmune process.
PTC and ATC cell lines release CXCL8 in basal conditions as well as under inflammatory stimuli,
such as IL-1 and TNF-α [40,85]. The exogenous induction of RET/PTC1 oncogene in primary normal
human thyrocytes induced the expression of CCL2, CCL20, and CXCL8 genes. CCL20 and CXCL8
were up-regulated in clinical samples of PTC [82]. PTCs displayed the highest expression of CCL20
and CXCL8 compared to normal tissues and thyroiditis, regardless of the genetic lesion beard by the
tumor [86]. In a model of orthotopic TC xenograft in nude mice, CXCL8 was involved in tumor growth
and progression [87]. Also, the tumor-infiltrating immune cells can be a source of chemokines. Indeed,
mast cell-derived CXCL8 in vitro induced EMT features and stemness in human TC cells [48]. TAMs
purified from PTC patients released CXCL8 [88].
PTC and ATC cell lines produce CXCL1/GRO-α and CXCL10/IP10 in basal conditions and
under inflammatory stimuli [81,83,89]. Moreover, mast cell-derived CXCL1/GRO-α (growth-regulated
oncogene α) and CXCL10/IP10 increased TC cell proliferation through the engagement of CXCR2
and CXCR3 on TC cells [47,81]. CXCL12/SDF-1 and its receptor CXCR7 have been found in PTC [90].
The CXCL12/SDF-1-CXCR7 axis promoted in vitro TC cell line proliferation and invasion [91]. Also,
CCL20 promoted TC cell invasion and migration in vitro [92]. Two splice variants of CXCR3 (A and
B), the receptor on follicular thyroid cells activated by several chemokines (CXCL4, CXCL9, CXCL10,
and CXCL11), have been found [93]. A progressive increase in CXCR3A expression over the CXCR2B
isoform was found from benign tumors to PTC.
We have found that the oncolytic adenovirus dl922-947 reduced CXCL8 and CCL2 production
by ATC cell lines. dl922-947 treatment impaired angiogenesis and favored the switch of tumor
macrophages toward an M1 phenotype. These results indicate that dl922-947 treatment, along with its
role in inducing TC cell death, has an impact on the ATC immune microenvironment.
5. Angiogenic and Lymphangiogenic Factors
The formation of blood and lymphatic vessels is a complex process, requiring a finely tuned
balance between stimulatory and inhibitory signals such as vascular endothelial growth factors
(VEGFs), angiopoietins (ANGPTs), chemokines, and many others [94–96]. Several TC-infiltrating
immune cells can impact tumor angiogenesis and lymphangiogenesis. Figure 1 shows that a plethora
of cytokines, chemokines, angiogenic factors, and lymphangiogenic factors derived from immune cells
enrich the complexity of the inflammatory tumor microenvironment in TC. For instance, mast cells
(MCs) are a major source of proangiogenic (VEGF-A and VEGF-B) and lymphangiogenic (VEGF-C
and VEGF-D) factors [97]. Thyroid MCs modulated angiogenesis through the release of CXCL8 [48].
Human macrophages are also a major source of both angiogenic and lymphangiogenic factors [98], as
well as of several proangiogenic enzymes such as matrix metallopeptidase 9 (MMP-9), cyclooxygenase
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-2 (Cox-2), andinducible nitric oxide synthase (iNOS) [44]. Tumor-associated NK cells produce VEGF-A
and CXCL8 [99]. Tumor-associated DCs release VEGF-A, CXCL8, and osteopontin [100]. Human
eosinophils promote angiogenesis [101,102], and eosinophilia can be observed in ATC patients [103].
Tregs play a role in maintaining tolerance in TC and drive tumor angiogenesis through the release
of VEGF-A [104]. Myeloid-derived suppressor cells (MDSCs) promote tumor angiogenesis through
the release of VEGF-A and MMP-9 [105]. Human Th2 cells and neutrophils are sources of angiogenic
factors [94,106,107].
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6. The Immune Landscape in TC
The tumor microenvironment (i.e., immune cells, fibroblasts, blood and lymphatic vessels,
endothelial cell progenitors, and extracellular matrix components (ECM)) plays a central role in tumor
initiation and progression. The normal tissue microenvironment can suppress malignancy, while
certain pathogenetic tissue features can induce tumor progression [111,112].
6.1. Tumor-Associated Macrophages (TAM)
Macrophages are key components of the tumor microenvironment and are highly plastic
cells [113–115]. Under the influence of IFN-γ, macrophages undergo M1 polarization, which is
characterized by an immunostimulatory phenotype. In contrast, IL-4 or IL-13 induce the M2 phenotype,
which promotes tumor angiogenesis and suppresses immune responses [44]. This model distinguishing
between classically polarized antitumor M1 and alternatively polarized M2 subtypes incompletely
accounts for the extraordinary phenotypic diversity of macrophages in vivo [116,117]. High-resolution
analysis of TAMCs led to the identification of 17 major phenotypes of human macrophages [116].
In PTCs, TAMs correlated with lymph node metastasis [88], larger tumor size [118], and reduced
survival. In PDTC, TAM density correlated with capsular invasion and extrathyroid extension [32].
TAMs represent more than 50% of immune cells in ATCs, forming a “microglia-like” in close contact
with cancer cells [31]. In the diffuse sclerosing variant of PTC, M2-like macrophages can be found in
lymphatic emboli and correlated with tumor cell lymphatic invasion [119].
Macrophages are present in the immune landscape of PTC, especially in the BRAFV600E+
group [120]. The histologic grading of CD68+ TAM increased in more aggressive thyroid cancers
(i.e., PDTC and ATC) compared to PTC [121]. In a murine model of transgenic BRAFV600E-induced
thyroid carcinogenesis, tumors displayed a high TAM infiltration due to the increased expression of
Csf-1r and Ccr2 by tumor cells. In this model, TAMs displayed an M2-like phenotype. In addition, Csf-1
−/− BRAF transgenic mice displayed a reduction in tumor growth [45]. TAMs purified from human
PTC displayed a higher expression of IL-10 and CD206 compared to peripheral blood monocytes [122],
and promoted the invasiveness of TC cell lines in vitro through the production of CXCL8 [88]. TAMs
are present in ATC to variable degrees, ranging from 22% to 95% [31,32,123]. ATCs and to a lesser
extent PDTCs have an extensive infiltration of macrophages [31,32], which make an interconnected
network that envelops the tumor cells throughout the cancer specimen. A total of 68 genes that were
overexpressed in M2 macrophages were examined in PDTCs and ATCs, and M2 signatures clearly
differentiated the two TCs [34]. The role of macrophages in the formation of lung metastasis has
been evaluated in an experimental model of ATC [124]. Macrophage depletion in mice injected with
clodronate reduced the lung metastasis of ATC cell lines. Metastasis-associated lung adenocarcinoma
transcript 1 (MALAT1) is a lung non-coding RNA that is up-regulated in several cancers, including
TC [125]. MALAT1 is up-regulated in TC tissues and cells, and induced the expression of basic fibroblast
growth factor (FGF2) and IL-10 in TAM, which promoted FTC133 proliferation and angiogenesis [126].
Soluble factors released by TC cell lines (TPC1, BC-PAP, and FTC133) induced an inflammatory
phenotype of peripheral blood monocytes [127]. Zhang et al. examined the protumorigenic role of
testosterone using the ThrbPV/PV transgenic mouse model, which mimics human FTC development.
They found that testosterone reduced the expression of the immune regulatory genes Glipr1 and Sfrp1,
the M1 macrophage, and CD8+ T cell infiltration in thyroid samples. These immunosuppressive events
resulted in TC progression in ThrbPV/PV mice [128]. These interesting findings were corroborated by
the analysis of the database of the National and Cancer Institute’s Surveillance Epidemiology End
Results (NIH, Bethesda, USA), which found that men had a higher rate of large primary or locally
advanced FTC than women. Furthermore, there was higher FTC-associated mortality in men than in
women in the 40-to-60-year age group.
High-dimensional analysis, particularly single-cell RNA-seq, will be necessary in order to better
characterize the role of macrophages in thyroid tumorigenesis.
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6.2. Dendritic Cells (DCs)
Tumor-infiltrating dendritic cells (DCs) display an immature phenotype, with impaired antigen
presentation ability [129]. S100+ (mature and immature), CD1a+ (immature), and CD83+ (mature)
DCs are increased in human PTC compared to normal thyroid tissue [130]. Conditioned media from
the primary cultures of PTC induced the chemotaxis of peripheral blood monocyte-derived DCs.
Hepatocyte growth factor (HGF) enhanced this chemotactic activity through the engagement of the
receptor Met on TC cells [131]. PTCs expressed the DC chemotactic molecule macrophage inflammatory
protein 1α (MIP-1α), and DCs expressed CCR6, thus suggesting a role for TC cells in recruiting DCs [132].
PTC displayed a higher CD1a+ DC infiltration compared to FTC and adenomas [132]. In contrast, a
reduced or absent DC infiltration in PDTC and ATC was described in comparison to DTC [133]. DCs
are present in the immune landscape of PTC, especially in the BRAFV600E+group [120].
6.3. Tumor-Associated Mast Cells (TAMCs)
Mast cells are ubiquitous in nearly all tissue and in close proximity to epithelia, fibroblasts,
blood vessels, lymphatic vessels, and nerves [95,134]. Mast cells can play a role in angiogenesis [134],
lymphangiogenesis [97], and tumor initiation and progression [110,135,136]. Mast cells are present in
the microenvironment of several solid [47,137–143] and hematologic tumors [144]). The contribution of
mast cells in cancer varies according to the stages of tumorigenesis and to their microlocalization [142].
Melillo et al. were the first to investigate the contribution of mast cells in thyroid cancer. Mast
cell density was very low in normal thyroid tissue, whereas in PTC samples, there was a mast cell
infiltration that correlated with tumor extrathyroid extension [47]. These findings were extended to a
limited number of PDTCs and ATCs [48]. The presence of mast cells in the immune landscape of PTC
has been recently confirmed [120].
A higher mast cell density was also found in FTC compared with adenomas and correlated
with extracapsular extension [145]. In vitro studies demonstrated that TC cell line conditioned media
induced mast cell chemotaxis through the release of VEGF-A [47], which activated the VEGFRs
on human mast cells [97,146]. Moreover, TC cells activated mast cells to release cytokines (IL-6,
TNF-α, granulocyte-macrophage colony-stimulating factor—GM-CSF) and chemokines (CXCL10/IP10
and CXCL1/Gro-α). In turn, mast cells promoted TC cell proliferation through CXCL1/GROα and
CXCL10/IP10. In an in vivo model of a TC xenograft, mast cells were recruited at the tumor site and
accelerated tumor growth, enhancing tumor vascularization and cell proliferation of the xenograft [47].
These results indicate that mast cells are present in human TCs and play a protumorigenic role in TC.
Epithelial-to-mesenchymal transition (EMT) is important in tumor progression, and is in part
responsible for the acquisition of the invasive properties of cancer cells [147]. A mast cell-conditioned
medium induced the EMT of human TC cell lines mainly through the release of CXCL8 [48]. Interestingly,
the blockade of CXCL8 receptors (i.e., CXCR1 and CXCR2) with blocking antibodies markedly reduced
the sphere-forming ability of TC cells [48]. Collectively, these findings support the hypothesis that
mast cell-derived CXCL8 favors the acquisition of stem-like features of TC cells.
Recent evidence indicates that mast cells, similar to macrophages [116,148] and neutrophils [107],
comprise several subsets of cells [149,150]. Single-cell RNA-seq analysis will be necessary to better
understand the role(s) of mast cells subsets in TC development and the formation of metastases.
6.4. Tumor-Associated Neutrophils (TANs)
Neutrophils participate in the early phases of inflammation and resistance against extracellular
pathogens [107,151], and play a role in cancer initiation and growth [152]. In humans, the ratio between
peripheral blood neutrophil and lymphocyte count (neutrophil-to-lymphocyte ratio—NLR) has been
proposed as an index of systemic inflammation, and has been found to be associated with tumor
development [153]. A higher NLR was associated with a larger tumor size and higher risk of recurrence
in TC patients, but failed to distinguish patients with benign or malignant nodules [154]. In contrast,
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an increased NLR has been found in TC compared with benign lesions and healthy controls [155].
No correlation was found with patient disease-free survival or risk of occult metastasis [156]. In a
large cohort of PTC, PDTC, and ATC, NLR was increased in ATC and to a lesser extent in PDTC [157].
In a meta-analysis based on seven prospective cohorts comprising 7349 patients, no difference in
NLR was found between DTC and patients with benign nodules [158]. Preoperative NLR was not
associated with clinicopathological characteristics in PTC patients [159,160]. By contrast, other studies
reported that the preoperative NRL was correlated with the size and lymph node metastasis of PTC
patients [161–164]. In conclusion, the diagnostic and prognostic significance of NLR in different types
of TC remains uncertain.
Maria Rosaria Galdiero et al. elegantly investigated the potential involvement of neutrophils in
human TC [165]. Conditioned media from TC cell lines TPC1 and 8505 (TC-CM) promoted human
neutrophils chemotaxis and survival. Neutrophil chemotaxis was mediated at least in part by CXCL8,
and survival was mediated by GM-CSF. TC-CM induced morphological changes and the activation of
neutrophils (i.e., CD11b and CD66 overexpression and CD62L shedding). Moreover, TC-CM induced
the production of ROS and angiogenic mediators (i.e., VEGF-A and CXCL8). Importantly, the density
of tumor-infiltrating neutrophils correlated with TC size. This study was the first to reveal the possible
involvement of neutrophils in human TC.
Due to their relatively low transcriptional activity and short lifespan [166], neutrophils are
generally believed to be terminally differentiated homogeneous cells once they leave the bone marrow.
This view is rapidly changing, and various subsets of neutrophils that are mostly defined by surface
markers [167] and density [168] have been described. Studies in murine models of cancer have
identified two functionally antagonistic populations of neutrophils, which are referred to as N1 and
N2 to mirror the nomenclature of M1 and M2 macrophages with similar activity [152]. The lack of
definitive cell markers of human N1 and N2 subsets has been so far a major obstacle to establish their
role in TC.
6.5. Myeloid-Derived Suppressor Cells (MDSCs)
Myeloid-derived suppressor cells (MDSCs) are largely immature myeloid cells that are
characterized by a state of activation and display potent immune suppressive activity [169]. Two
major subsets of MDSCs have been identified so far: monocytic (M-MDSCs) and polymorphonuclear
(PMN-MDSCs) [170]. M-MDSCs share phenotypic and morphologic features with monocytes, whereas
PMN-MDSCs are similar to neutrophils. MDSCs have been implicated in tumor immune responses,
tumor initiation and progression, angiogenesis, and the formation of pre-metastatic niches [169,170].
MDSCs inhibit anti-cancer immune responses by releasing cytokines (IL-1 and TGF-β), ROS, and
reactive nitrogen species (RNS) that condition the tumor microenvironment and by stimulating
Foxp3+ Treg cells and M2 tumor-associated macrophages (TAM) [171]. Moreover, MDSCs promote
angiogenesis and condition the pre-metastatic niches [170]. M-MDSCs and PMN-MDSCs differentiate
from normal progenitors of monocytes and neutrophils, respectively [172]. Recently, PMN-MDSCs
were distinguished from human neutrophils by the expression of the lectin-type oxidized LDL receptor 1
(LOX-1). LOX-1+ neutrophils were potent suppressor of T cells, while LOX-1− neutrophils, presumably
classical neutrophils, were not [173,174].
Peripheral blood MDSC levels were increased in patients with ATC compared to healthy controls
and correlated with the serum level of IL-10, suggesting a correlation between MDSCs and systemic
immunosuppression [175]. MDSCs are attracted to tumor sites in response to various cytokines
(CCL2, CCL5, and CSF1 for M-MDSCs, and CXCL1, CXCL5, CXCL6, CXCL8, and CXCL12 for
PMN-MDSCs) [176]. In tumors, the incoming cells dive into a fairly hostile microenvironment
characterized by hypoxia, low pH, and high concentrations of cytokines, lactate, adenosine, and
oxidative agents (ROS, NO) [176,177]. These conditions heavily affect MDSC survival, functions, and
differentiation. It is generally thought that PMN-MDSCs in tissues are short-living cells, and that
monocytic cells in the tumor microenvironment most likely represent bona fide M-MDSCs. In a wide
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cohort of TC patients (253 PTCs and 13 FTCs), the intratumoral MDSCs count, which were identified
as CD11b+ and CD33+ cells, did not correlate with patient clinicopathological features [178]. Two
studies did not find increased peripheral blood MDSCs, which were defined as CD11b+ CD33+ cells,
in PTC patients compared to control, but showed accumulation in patients with ATC [175,179]. More
recently, circulating CD11b+ HLA-DRlow (presumably PMN-MDSCs), but not CD33+ HLA-DRlow
(presumably M-MDSCs), were increased in DTC, mostly PTC, compared to benign nodules [180].
The lack of definite cell markers for human MDSC subsets has been so far a major obstacle to establish
their clinical significance in TC patients. Single-cell RNA-seq will be needed to identify subsets of
M-MDSCs and PMN-MDSCs in different types of human TCs.
A mouse model HrasG12V/Pten/TPO-Cre developed multifocal FTC, which displayed many of
the classical hallmarks of high-grade human FTC and PDTC, including an extrathyroidal extension
and lung metastasis [181]. These tumors were heavily infiltrated by macrophages, MDSCs, and
double-positive CD4+ CD25+ T cells (Treg cells), and contained arginase-1+ cells. These findings are
suggestive of an immunosuppressive tumor microenvironment (TME) of TC.
6.6. Natural Killer (NK) Cells
Natural killer (NK) cells are a family of innate immune cells that play crucial roles in protective
immunity against tumors and viral infections [182]. Subtypes of human NK cells have been identified
on the basis of the relative surface expression of CD16 and CD56. CD56dim CD16+ NK cells display
a higher cytotoxic activity, whereas CD56bright CD16−/low NK cells are more efficient in cytokine
production [183]. Tumor-infiltrating NK cells were increased in PTCs compared to goiters and healthy
thyroids, whereas no differences were found in peripheral blood NK cells [184,185]. In PTC patients,
NK cell infiltration negatively correlated with disease stage [186]. An increased infiltration of the
immunoregulatory subset of NK cells CD56bright was found in PTC samples compared to MNG.
CD56bright NK cells inversely correlated with the disease stage, whereas cytotoxic NK cells positively
correlated with the disease stage in PTC patients. These results indicate that the TC microenvironment
modulates the phenotype of NK cells [187].
NK cells mediated the lysis of ATC cell lines through the expression of the activating receptor
NKG2D on NK cells and its ligands UL16 binding proteins (ULBP2/5/6) on ATC cells [188]. ATC cell
lines and TC derived from human fine-needle aspiration [189] samples from ATC patients expressed
ULB2/5/6, whereas non-malignant thyroid tissue did not. ATC cell lines induced NK cell migration
through the activation of the CXCL10–CXCR3 axis. NK cells from FNA and the peripheral blood of
ATC patients displayed a suppressed phenotype, which was characterized by a lower percentage of
CD56dim cells and CXCR3+ cells and a reduced NKG2D expression, compared to peripheral blood
NK cells. PGE2 produced by thyroid cancer cells [190] can be responsible for ATC-mediated NK cell
suppression [188]. A recent study found a decrease frequency of peripheral blood cytotoxic NK cells
(i.e., CD56lo CD16hi) in ATC patients compared to controls [191]. By contrast, NK cells CD56hi CD16lo/hi
(cytokine producing) were increased in ATC compared to non-ATC patients and healthy controls.
In a knock-in mouse model, BRAF oncogene was expressed under the control of the thyroid
peroxidase (TPO) promoter (LSL-BRAFV600E/TPO Cre mice). IL-12 gene therapy and recombinant IL-12
reduced tumor growth, restored the follicular architecture of the gland, and improved the survival of
tumor-bearing mice. Interestingly, IL-12 improved the cytotoxicity of CD8+ T cells and NK cells, and
increased the infiltration of M1 macrophages within the tumors [61]. NK cells inhibited the growth of
metastasis in an in vivo mouse model of ATC pulmonary metastasis [192].
6.7. Natural Killer T Cells (NKT)
NKT cells are a heterogeneous lymphoid population that recognizes the lipid antigens presented
by CD1d and plays an important role in tumor immunosurveillance [193]. Two NKT subsets have
been identified: type I induce the lysis of tumor cells directly via a perforin/granzyme B-mediated
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mechanism or indirectly via the activation of NK cells and DCs; type II show immunosuppressive
activity through the production of IL-13 [194]. NKT subsets have not been characterized in TC.
6.8. γδ T Cells
γδ T lymphocytes, expressing a γδ T cell receptor (TCR), are not MHC-restricted and do not
recognize peptide antigens [195]. The contribution of γδ T cells in tumor immunosurveillance is
controversial. Zitvogel et al. demonstrated that IL-17-producing γδ T cells play a prominent role in
chemotherapy-induced anti-cancer immune responses [196]. The role of tumor-infiltrating γδ T cells in
TC is still unknown.
6.9. Innate Lymphoid Cells (ILCs)
Innate lymphoid cells (ILCs) lack TCR, but functionally resemble effector T cells [197]. ILCs
include three subsets of cytokine-producing helper cells: group 1 ILCs produce IFN-γ and include
conventional NK cells; group 2 produces Th2-type cytokines (e.g., IL-4, IL-5, and IL-13); group 3 ILCs
comprises several distinct cell subsets [198]. ILCs have a critical role in the development of lymphoid
structures, the maintenance of immune homeostasis, tissue remodeling, and the maintenance of
epithelial integrity [199]. ILCs have also been implicated in the control and suppression of tumors [200].
There is evidence that the tumor microenvironment dictates the fate of the tumor-suppressive functions
of ILC2. Moreover, ILC2 can modulate T cell-to-MDSC balance in cancer [201]. Studies are required to
understand the role of ILC subsets in different TCs.
6.10. CD8+ Cytotoxic T Cells
CD8+ cytotoxic T lymphocytes (CTLs) recognize and attack tumor cells expressing tumor
antigens [202]. In a wide immunohistochemical characterization of the immune network in patients
with chronic lymphocytic thyroiditis concurrent with DTC, a high CD8+ T lymphocyte infiltration was
associated with improved disease-free survival [178]. In a study conducted in a wide cohort of DTC
patients, including papillary and follicular subtypes, immunohistochemical analysis of tumor samples
revealed that the combined enrichment of CD8+ cells and Cox-2 overexpression correlated with the
highest risk of disease relapse. In the majority of the tumor samples analyzed (68%), CD8+ cells were
granzyme B negative, reflecting a state of anergy [203].
A low intratumoral CD8+/Foxp3+ ratio was found in human BRAFV600E PTC, which was
associated with an increased expression of the immunosuppressive molecules arginase-1, indoleamine
2,3-dioxygenase (IDO), and programmed death-ligand 1 (PD-L1). The latter findings suggest a
BRAF-driven tumor-promoting microenvironment [204]. A recent study evaluated the CXCR5+
CD8+ T cell subset in peripheral blood, tumor-draining lymph nodes (TDLNs), and tumors from TC
patients [205]. Although CXCR5+ CD8+ T cells expressed higher PD-1, T-cell immunoglobulin and
mucin-domain containing-3 (TIM-3), and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) markers than
CXCR5− CD8+ T cells, these cells displayed a higher expression of cytotoxic molecules (e.g., granzymes
and perforin).
6.11. CD4+ Cells
The role of different subsets of CD4+ T cells in tumor immunity remains underappreciated.
Th1-mediated immunity is generally considered as antitumoral [206], while polarized Th2 and/or Treg
activity is believed to be protumorigenic [207]. This simplistic view is complicated by the plasticity
of Th differentiation, which can be extensively modulated by the tumor microenvironment [115,208].
In TC, the extent of tumor-infiltrating CD4+ cells does not appear to predict patient outcome [203].
No differences were found between PTC and MNG patients, with respect to tissue or peripheral blood
CD4+ cell frequencies [53]. Interestingly, a double negative CD4− CD8− lymphocyte population was
the dominant cell type in PTC, and was more abundant in PTC than in thyroid autoimmunity and ex
vivo released IFN-γ and IL-17 [209].
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6.12. Treg Cells
Tregs shut down antitumor immune response via the production of IL-10, the expression of
immunosuppressive molecules (e.g., CTLA-4 and PD-1), and the stimulation of angiogenesis [210].
Moreover, increased PD-1+ T and Treg cells in metastatic lymph nodes correlated with a more aggressive
TC [211]. Foxp3+ Tregs and VEGF were found in PTC samples, and Treg infiltration correlated with
disease stage and lymph node metastasis [212]. A higher Treg density was also observed in PTC
samples compared with nodular goiter, and positively correlated to the stage of the disease [186].
Accordingly, a high infiltration of Foxp3+ Treg cells was associated with aggressive features of PTC [213].
Moreover, increased Foxp3+ and reduced CD3+ tumor-infiltrating lymphocytes correlated with IDO1
expression. Similarly to PD-L1, IDO1 is overexpressed in different tumors, and is associated with
the activation of Foxp3+ Tregs and the down-regulation of cytotoxic cellular immunity in the tumor
microenvironment [214].
A higher percentage of Foxp3+ T cells and Inducible T-cell COStimulator (ICOS) + Treg cells
were found in tissues, but not in the peripheral blood of PTC patients with MNG compared to MNG
alone [53]. In PTC plus MNG, tissue ICOS+ Foxp3+ T cells were increased in advanced stages and
metastatic tumors. Tissue ICOS+ Foxp3+ T cell numbers correlated with tissue plasmocytoid DCs,
which favor an immunosuppressive microenvironment [53].
6.13. IL-17+ Cells
CD4+ IL-17+ T cells (Th17) cells can exert protumor or antitumor functions, depending on the
tissue microenvironment [215]. Only one study examined the prevalence and distribution of Th17
cells in TC samples. In peripheral blood and tissue samples of PTC patients, increased Th17 levels
were found compared to healthy controls, whereas the percentage of CD8+IL-17+ T cells (Tc17) in the
peripheral blood was reduced. The frequency of peripheral blood Th17 cells was positively correlated
with the IL-17 serum level, while no correlation between the serum level of IL-17 and Tc17 cells was
found. Peripheral blood Th17 cells inversely correlated with tumor size [62].
6.14. T Follicular Helper Cells (Tfh)
T follicular helper cells (Tfh) were discovered based on their expression of the essential transcription
factor BCL6 [42,216]. This led to the recognition of Tfh cells as an independent CD4+ subset specialized
in helping B cells in lymph nodes [42,217]. No single marker or combination of markers reliably
identifies Tfh cells as a discrete immune cell population. In fact, Tfh are part of the CD4+ T cell
differentiation spectrum. Several surface molecules (CCR5, PD-1, BCL6, BTLA4, and ICOS) vary in
expression and represent plastic features of Tfh heterogeneity. A fraction of CD4+ T cells in human
blood express CXCR5 or PD-1 and are called circulating Tfh (cTfh) cells. The latter cells are closely
related to tissue Tfh cells. Human cTfh are heterogeneous [42], and are divided into three major
functional subtypes (Tfh1, Tfh2, and Tfh17) [218]. IL-21 is a B-cell helper cytokine produced by Tfh
cells [219].
Overreactive Tfh cells have been reported in several human systemic autoimmune diseases [220].
An increased frequency of cTfh cells has been reported in patients with autoimmune thyroid disease,
and Tfh cells were also detected in the thyroid tissue of Hashimoto’s thyroiditis patients [221]. CXCR5+
CD4+ T cells were increased in the thyroid tissue of patients with Graves’ disease compared to control
subjects [222]. Furthermore, CD4+ IL-21R+ T cells and CD19+ IL-21R+ B cells were also observed in
Graves’ disease tissues.
Recent studies suggested that Tfh cell infiltrates may influence the growth and survival of certain
tumors [223,224]. To our knowledge, the characterization of different subtypes of circulating and
intratumor Tfh in different types of TC has not been reported yet. Future studies should investigate
the presence and functions of Tfh subsets in different types of TC.
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6.15. Th9 Cells
IL-9-producing CD4+ helper T cells (Th9 cells) are a subset of CD4+ helper T cells with
proinflammatory functions and anti-cancer properties in vivo [225]. The release of IL-9 has been
proposed to account for anti-cancer efficacy. Moreover, Th9 cells release IL-21, which promotes the
production of IFN-γ and tumor elimination by CD8+ T cells and NK cells [226]. The Th9 antitumor
efficacy has been attributed to the production of IL-9 [227]. Studies investigating the relevance of Th9
cells in thyroid oncogenesis are urgently needed. Figure 2 schematically illustrates a hypothetical
immune landscape of TC.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 31 
 
cells in thyroid oncogenesis are urgently needed. Figure 2 schematically illustrates a hypothetical 
immune landscape of TC. 
 
Figure 2. Schematic representation of the rationale developing combinatorial therapies of advanced 
thyroid cancer involving immune checkpoint inhibitors (monoclonal antibodies (mAbs) anti-
cytotoxic T lymphocyte antigen 4 (anti-CTLA-4), anti-programmed cell death protein-1 (anti-PD-1), 
or anti-programmed cell death ligand-1 (anti-PD-L1)), BRAF inhibitors (BRAFi), multi-targeted 
tyrosine kinase inhibitors (TKIs) (e.g., lenvatinib), chemotherapies, or radiotherapies. (A) Cancer cells 
release neoantigens (dots of different colors) that are captured by antigen-presenting cells (APCs). 
These cells present peptides in the context of MHC I molecule/T cell receptor (TCR) on the surface of 
CD8+ cytotoxic T cells. APCs can also present peptides bound to MHC II molecules on CD4+ T helper 
cells. T-cell activation requires costimulatory signals transmitted via CD28, which is activated by 
binding to CD80 and/or CD86 on APCs. Tumor cells up-regulate CTLA-4 on T cells, which competes 
with CD28 for binding to CD80/CD86 on APCs. The interaction of CTLA-4 with CD80/CD86 results 
in inhibitory signaling in T cells, which favors thyroid cancer cell proliferation. The 
immunosuppressive activity of CTLA-4 is mediated by the down-regulation of Th cells and the 
enhancement of Treg cells. Moreover, tumor cells express high levels of PD-L1 and/or PD-L2, which 
binds to PD-1 on T cells, resulting in inhibitory signals that decrease cytotoxicity and lead to T-cell 
exhaustion. (B) mAbs blocking CTLA-4 (e.g., ipilimumab, tremelimumab), PD-1 (nivolumab, 
pembrolizumab, spartalizumab), or PD-L1 (avelumab, atezolizumab, durvalumab) inhibit the 
interactions of CTLA-4/CD80/86 and PD-1/PD-L1, respectively, and activate T-cell cytotoxicity. BRAF 
inhibitors (BRAFi), TKIs (e.g., lenvatinib), chemotherapies, and radiotherapies can induce thyroid 
cancer cell death, increasing the release of tumor neoantigens in the tumor microenvironment. 
Combining an anti-PD-L1 antibody with BRAFi [228,229] or with lenvatinib [229] improved survival 
and tumor immunity in a immunocompetent murine model of ATC. Several combination strategies 
involving immune checkpoint inhibitors (ICIs) are under evaluation in patients with advanced TC 
(see Table I and II). 
7. Immune Checkpoint Inhibitors in TC 
Figure 2. Schematic representation of the rationale e eloping combinatorial therapies of advanced
thyroid cancer involving immune checkpoint inhib tors (monocl nal ntibodies (mAbs) anti cytotoxic
T lymphocyte antigen 4 (anti-CTLA-4), anti-programmed cell death protein-1 (anti-PD-1), or
anti-programmed cell death ligand-1 (anti-PD-L1)), BRAF inhibitors (BRAFi), multi-targeted tyrosine
kinase inhibitors (TKIs) (e.g., lenvatinib), chemotherapies, or radiotherapies. (A) Cancer cells release
neoantigens (dots of different colors) that are captured by antigen-presenting cells (APCs). These cells
present peptides in the context of MHC I molecule/T cell receptor (TCR) on the surface of CD8+ cytotoxic T
cells. APCs can also present peptides bound to MHC II molecules on CD4+ T helper cells. T-cell activation
requires costimulatory signals transmitted via CD28, which is activated by binding to CD80 and/or
CD86 on APCs. Tumor cells up-regulate CTLA-4 on T cells, which competes with CD28 for binding to
CD80/CD86 on APCs. Th interaction of CTLA-4 with CD80/CD86 results in inhibitory signaling in T
cells, which favors hyroid cancer cell proliferation. The immunosuppressive activity of CTLA-4 is
mediated by the down-regulation of Th cells and the enhancement of Treg cells. Moreover, tumor cells
express high levels of PD-L1 and/or PD-L2, which binds to PD-1 on T cells, resulting in inhibitory signals
that decrease cytotoxicity and lead to T-cell exhaustion. (B) mAbs blocking CTLA-4 (e.g., ipilimumab,
tremelimumab), PD-1 (nivolumab, p mbrolizumab, spartalizumab), r PD-L1 ( velumab, atezolizumab,
durvalum b) inhibit the i ter ctions of CTLA-4/CD80/86 and PD-1/PD-L1, respectively, a d activate
T-cell cytotoxicity. BRAF inhibitors (BRAFi), TKIs (e.g., lenvatinib), chemotherapies, and radiotherapies
can induce thyroid cancer cell death, increasing the release of tumor neoantigens in the tumor
microenvironment. Combining an anti-PD-L1 antibody with BRAFi [228,229] or with lenvatinib [229]
improved survival and tumor immunity in a immunocompetent murine model of ATC. Several
combination strategies involving immune checkpoint inhibitors (ICIs) are under evaluation in patients
with advanced TC (see Tables 1 and 2).
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Table 1. Clinical Trials Evaluating the Effects of PD-1 Inhibitors in Thyroid Cancer.
Clinical Trial Registry
NCT Number PD-1 Inhibitor Combination Study Phase
NCT03246958 Nivolumab Nivolumab + Ipilimumab Phase 2
NCT02834013 Nivolumab Nivolumab + Ipilimumab Phase 2
NCT03274258 Nivolumab Nivolumab + Ipilimumab Phase 2
NCT03866382 Nivolumab Nivolumab + Ipilumab Phase 2
NCT02688608 Pembrolizumab Pembrolizumab Phase 2
NCT03072160 Pembrolizumab Pembrolizumab Phase 2
NCT03360890 Pembrolizumab Pembrolizumab + Chemotherapy Phase 2
NCT03211117 Pembrolizumab Pembrolizumab + Chemotherapy
+ Radiation Phase 2
NCT02973997 Pembrolizumab Pembrolizumab + Lenvatinib Phase 2
NCT03012620 Pembrolizumab Pembrolizumab Phase 2
NCT03435952 Pembrolizumab Pembrolizumab + ClostridiumNovyi-NT Phase 1
NCT02628067 Pembrolizumab Pembrolizumab Phase 2
Table 2. Clinical Trials Evaluating the Effects of PD-L1 Inhibitors in Thyroid Cancer.
NTC Number PD-L1 Inhibitor Combination Study Phase
NCT03181100 Atezolizumab Atezolizumab + Chemotherapy Phase 2
NCT03170960 Atezolizumab Atezolizumab + Cabozantinib Phase 1 and 2
NCT03217747 Avelumab Avelumab + Chemotherapy Phase 1 and 2
NCT03753919 Durvalumab Durvalumab + Tremelimumab Phase 2
NCT03215095 Durvalumab Durvalumab + Radioiodine Phase 1
NCT03122496 Durvalumab Durvalumab + Radiotherapy Phase 1
7. Immune Checkpoint Inhibitors in TC
Immune checkpoints physiologically prevent excessive immune responses and the development
of autoimmunity [230–232]. Monoclonal antibodies (mAbs) targeting immune checkpoints (immune
checkpoint inhibitors: ICIs) have revolutionized the treatment of malignancies characterized by DNA
microsatellite instability [233]. Two major classes of ICIs have clinically emerged: those targeting
cytotoxic T lymphocyte antigen 4 (CTLA-4) (i.e., ipilimumab and tremelimumab), and those targeting
programmed cell death protein-1 (PD-1) (i.e., nivolumab, pembrolizumab, spartalizumab) or its ligand,
programmed cell death ligand-1 (PD-L1) (i.e., avelumab, atezolizumab, and durvalumab). CTLA-4
and PD-1 regulate different stages of the immune response. For instance, CTLA-4 modulates immune
response primarily in draining lymph nodes, whereas the primary site of action of PD-1 and its ligands
(PD-L1/PD-L2) is in the tumor microenvironment (TME). PD-1 expressed on activated T cells interact
with PD-L1 or PD-L2 expressed on the surface of cancer cells or tumor-infiltrating immune cells,
thus inhibiting the cytotoxic action of T cells [234]. The up-regulation of PD-L1 by tumor cells leads
to increased T-cell exhaustion, and is thought to be a means of cancer cell immune evasion [235].
When T cells are primed by exposure to antigens presented by APCs in draining lymph nodes, they
become activated and overexpress CTLA-4 on their surfaces, which competes with CD28 for binding
to CD80 or CD86 on the surface of APCs. This competition between CTLA-4 and CD28 attenuates the
early activation of CD4+ and CD8+ T cells, and improves the immunosuppressive functions of Treg
cells [236]. Figure 2A schematically illustrates the two interactions between CTLA-4 on T lymphocytes
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and CD80/CD86 on APCs and between PD-1 on T cells and tumor cells expressing PD-L1 or PD-L2.
Both interactions result in inhibitory signals that lead to T-cell exhaustion, decreased T-cell cytotoxicity,
and cancer cell proliferation.
The PD-1/PD-L1 pathway is expressed in ATC and DTC [237,238]. BRAFV600E cells express higher
expression of PD-L1 compared to BRAFWT cells [228]. The low rate of mutations—and therefore, of
neoantigens in DTC—might suggest that this would be a poor target for monotherapy with ICIs [239].
In fact, the results of a preliminary trial of the PD-1 inhibitor pembrolizumab in patients with PD-L1+
PTC or FTC confirmed that hypothesis [240]. More recently, higher numbers of mutation load and
genetic alterations have been identified in poorly DTCs and ATC than in DTCs [34]. To increase
the response rate of ICIs, a major focus is to find combinations that act synergistically. For example,
combination strategies that target multiple aspects of the immune response (e.g., PD-1/PD-L1 and
CTLA-4 pathways) or tumor cells themselves (e.g., tyrosine kinase inhibitors, BRAF inhibitors,
radiotherapy) could provide benefits for patients with advanced thyroid disease.
Brauner et al. found that combining the BRAF inhibitor and anti-PD-L1 antibody markedly
improved tumor immunity (e.g., CD8+ cell infiltration and CD8+: Treg ratio) and tumor regression in
an immunocompetent murine model of ATC. These findings were extended in an immunocompetent
model of orthotopic murine ATC by showing that the combination of the BRAF inhibitor (i.e., PLX4720)
and anti-PD-1/PD-L1 mAbs reduced tumor volume and improved survival [241]. Moreover, the
combination of lenvatinib—a multi-tyrosine kinase (TK) inhibitor—with anti-PD-1/PD-L1 mAb
reduced tumor volume and improved survival in immunocompetent mice with orthotopic ATC [229].
This combination treatment was associated with an increase in tumor-infiltrating CD8+ T cells and
granzyme B staining without changes in NK cells. Preliminary studies indicate that the combination
of a mAb anti-PD1 (i.e., pembrolizumab) with a TK inhibitor may be an effective salvage therapy for
the treatment of ATC [242]. Several ongoing clinical trials are evaluating the strategies that target
PD-1 alone or in combination with CTLA-4 inhibitor (ipilimumab), chemotherapy, radiation, or TKI
(lenvatinib) in advanced TCs (Table 1). Other clinical trials are evaluating the effects of PD-L1 inhibitors
(avelumab, atezolizumab, and durvalumab) in combination with CTLA-4 inhibitor (tremelimumab),
chemotherapy, or radiotherapy in advanced TCs (Table 2). Figure 2B schematically illustrates the
rationale of combinatorial therapies of advanced TC involving ICIs, BRAFi, multi-targeted TKIs,
chemotherapies, or radiotherapies.
8. Thyroid Disorders Induced by ICIs
CTLA-4-knockout mice often develop autoimmune diseases, such as pancreatitis and
myocarditis [243]. Similar to CTLA-4, mouse models lacking expression of PD-1 have distinct
autoimmune phenotypes, such as lupus-like syndromes or dilated cardiomyopathy [244,245].
In humans, inactivating CTLA-4 (i.e., ipilimumab) is linked with a wide array of autoimmune
disorders including thyroiditis [246–251]. Immune-related adverse events (irAEs) associated with
inhibitors of PD-1/PD-L1 axis tend to be more limited in severity and incidence, but have an earlier
onset than the adverse effects of CTLA-4 inhibition associated with these agents, which are sometimes
severe and can occur during treatment or even long after treatment cessation [230]). Hypothyroidism
is more common with anti-PD-1 antibodies than ipilimumab (4–10% versus 2–4% respectively), is
rarely severe [252–258], and occurs commonly after subclinical hyperthyroidism [259–261].
9. Outstanding Questions and Conclusions
During the last years, the incidence of TC has increased, and it now represents approximately 90%
of all endocrine malignancies and 70% of deaths due to endocrine cancers [2]. While the prognosis
of DTC is favorable, PDTC and ATC are among the most lethal human malignancies. Nearly all
immune cells are present in the TC microenvironment, and in some cases are associated with patient
outcome [32,47,121,123,124]. Studies assessing the functional role of TAMs, TAMCs, and TANs have
provided evidence for their protumorigenic role [45,47,165]. The majority of these studies were merely
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quantitative and qualitative analyses of immune cells in the TME of TC. Unfortunately, the presence
and functional role(s) of several subsets of immune cells (e.g., NKT and γδ T cells, Tfh, Th9, Th17, and
Tc17), which are known to be relevant for tumor initiation and growth, have not yet been investigated
in the microenvironment of different types of TC.
Macrophages are key components of the TC microenvironment, and TAM and M2 macrophages
are associated with more aggressive cancers (PDTC and ATC) [121], larger tumor size [118], lymph
nodes [88], and lung metastases [124]. However, increasing evidence indicates that TAMs comprise
more than two (M1 and M2) subsets of cells [116,148]. Mast cell density in human PTC and FTC
correlated with tumor extrathyroid extension [47,145]. Mast cells, similar to macrophages, also
comprise several subsets of cells [149,150]. Therefore, single-cell RNA-seq will be necessary in order to
understand the role of different subsets of macrophages and mast cells in thyroid tumorigenesis and as
biomarkers of response to ICIs in patients with advanced disease.
Increasing evidence indicates that neutrophils, which were originally believed to be homogeneous
and terminally differentiated cells, are involved in tumor immunity [107,152]. Several studies have
simplistically suggested that the NLR could be associated with clinicopathological characteristics of
TC patients. The significance of NLR in different types of TC remains uncertain. Galdiero et al. have
demonstrated that neutrophils are present in human TC, and TC-CM promoted their activation [165].
Further studies are urgently needed to explore the role of subsets (e.g., low-density, high-density, N1,
N2) of neutrophils in different types of TC.
MDSC, similar to macrophages, mast cells, and neutrophils, comprise at least two subsets of
cells (i.e., PMN-MDSC and M-MDSC) [170]. PMN-MDSCs in tissues are considered short-living cells,
whereas MDSCs in the tumor microenvironment likely represent bona fide M-MDSCs. Unfortunately,
the lack of definitive markers for subsets of human MDSCs has so far prevented establishing their exact
role in different types of TC. NK cells play a central role in immune surveillance against tumors, and
comprise at least two subsets (i.e., CD56hi CD16lo/hi and CD56lo CD16hi). In a mouse model of ATC, it
was shown that NK cell-based immunotherapy is an effective therapy of pulmonary metastases [192].
TK inhibitors targeting RET or BRAF can induce either stable disease or partial responses in
PTC and FTC metastatic patients, but are much less effective in ATC [9,262]. Therefore, alternative
therapeutic approaches for these TC histotypes are needed. A possible approach is represented by
drugs targeting the interactions between immune cells and cancer cells and/or tumor stromal cells,
including immune cells. Various immunologic approaches are under evaluation in preclinical studies
or in early phase clinical trials for the treatment of ATC. Preclinical and preliminary clinical studies
have reported encouraging results on the efficacy of mAbs targeting the PD-1/PD-L1 network [228].
The rationale of this immunologic approach is based on the expression of the PD-1/PD-L1 pathway in
DTC and ATC [237,238]. A promising strategy is the immunotherapy combined or sequenced with
targeted therapy in the treatment of tumors [263,264]. Preliminary results suggest that combining
BRAF inhibitor and anti-PD-1 mAb can improve immunity in a murine model of ATC [229]. Similarly,
the combination of a TK inhibitor with anti-PD-1/PD-L1 mAbs improved survival in a murine model
of ATC [229]. Figure 2 schematically illustrates the rationale for the antitumor effect of BRAF or TK
inhibitor in combination with ICI.
Several other immune checkpoint receptors such as TIM-3, Lymphocyte-activation gene 3 (LAG-3),
T Cell Immunoreceptor With Ig And ITIM Domains (TIGIT), B- and T-lymphocyte attenuator (BTLA),
V-domain Ig suppressor of T cell activation (VISTA), sialic acid-binding immunoglobulin-type lectins
(SIGLEC) 9 and 7, and P-selectin glycoprotein ligand (PSGL)-1 have been identified to be potential
therapeutic targets in the immunotherapy of tumors [265]. mAbs targeting the above immune
checkpoints are under evaluation in preclinical and/or clinical studies, and should be considered also
for the treatment of ATC.
TC cells and several immune cells are a major source of protumorigenic and pro-angiogenic
cytokines and chemokines [97,98]. Anti-angiogenic agents, eventually in combination with ICIs, could
be exploited to block TC growth, since this strategy has been already developed for other tumors [266].
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Moreover, blocking immunosuppressive molecules (TGF-β, IL-10) expressed either by cancer cells or
by tumor-infiltrating immune cells [267] could represent another therapeutic strategy for the treatment
of TC.
Oncolytic viruses (OVs) are non-pathogenetic viral stains or viral mutants that selectively replicate
in and kill tumor cells without causing damage to normal cells [268]. The OV dl922-947 reduced CXCL8
and CCL2/MCP-1 expression and inhibited angiogenesis and macrophage infiltration in ATC [269].
The Food and Drug Administration (FDA) has approved the first OV to treat patients with advanced
melanoma [270]. Preclinical and clinical studies appear necessary for evaluating ATC virotherapy in
the context of TC immunotherapy.
Most of the in vivo experimental studies of TC have been performed with athymic nude mice
models. Studies conducted with these models have demonstrated a protumorigenic role of mast cells
in human TC [47,48]. The protumorigenic role of macrophages in TC has been established in mice in
which macrophage depletion has been obtained by either pharmacological or genetic tools [45,124].
Genetically modified mouse models of TC should be employed to better characterize the role of
different immune cell subsets in different stages of tumorigenesis [271].
Extraordinary progress has been made in recent years in the characterization of several, but not all,
cells of the immune system in the tumor microenvironment of different TCs. Moreover, it is becoming
clear that different subtypes of immune cells play a protumorigenic role, whereas other types play a
protective role in TC. Single-cell analysis of peritumoral and intratumoral immune cells could help to
elucidate the functions of subsets of cells in different types of TC. The result that will emerge from these
studies will contribute to elaborate targeted immunotherapy strategies for the treatment of advanced
thyroid cancer.
Author Contributions: G.V., M.R.G., and G.M. wrote the initial draft. S.L., L.M., P.F., S.M.F., A.d.P., and A.A. made
substantial contributions and discussed the content. All the authors reviewed the manuscript prior submission.
Funding: This work was supported in part by grants from the CISI-Lab Project (University of Naples Federico II),
the CRèME Project, and the TIMING Project (Regione Campania) (G.M.) and from MIUR-PRIN 2017M8YMR8_005
(M.R.G.).
Acknowledgments: The authors apologize to the many researchers who have contributed importantly to this
field and whose work has not been cited due to space and citation restrictions. The authors thank Gjada Criscuolo
for the critical reading of the manuscript, scientists from CISI Laboratory not listed as authors for invaluable
collaborations, medical graphic artist Fabrizio Fiorbianco for preparing the figures, and the administrative staff
(Roberto Bifulco and Anna Ferraro), without whom we could not function as an integrated team.
Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or
financial relationships that could be construed as a potential conflict of interest.
Abbreviations
ALK anaplastic lymphoma kinase
ANGPT angiopoietin
ATC anaplastic thyroid carcinoma
CTL cytotoxic T lymphocyte
CTLA-4 cytotoxic T lymphocyte antigen 4
DCs dendritic cell




FTC follicular thyroid cancer
GM-CSF granulocyte-macrophage colony-stimulating factor
HGF hepatocyte growth factor
HTT hyalinizing trabecular tumor
ICI immune checkpoint inhibitor
IDO1 indoleamine 2,3-dioxygenase 1
Int. J. Mol. Sci. 2019, 20, 3934 17 of 31
IFN interferon
ILC innate lymphoid cell
INF interferon
mAb monoclonal antibody
MDSC myeloid-derived suppressor cell
MMP metalloproteinase
MNG multinodular goiter
MTC medullary thyroid cancer
NGS next-generation sequencing
NK natural killer
NKT natural killer T cell
NLR neutrophil-to-lymphocyte ratio
NSCLC non-small-cell lung cancer
OS overall survival
PD-1 programmed cell death protein-1
PD-L1 programmed cell death ligand-1
PDTC poorly differentiated thyroid cancer
PMN polymorphonuclear cell
PTC papillary thyroid cancer
RET REarranged during Transfection
RNS reactive nitrogen species
ROS reactive oxygen species
SCF stem cell factor
TAM tumor-associated macrophage
TAMC tumor-associated mast cell
TAN tumor-associated neutrophil
TC thyroid cancer
TCR T cell receptor
TDLN tumor-draining lymph node
Tfh T follicular helper cell
Th T helper cell
TK tyrosine kinase
TKI tyrosine kinase inhibitor
TME tumor microenvironment
TNF-α tumor necrosis factor-α
Treg regulatory T cell
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
References
1. Fagin, J.A.; Wells, S.A., Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N. Engl. J. Med. 2016, 375, 1054–1067.
[CrossRef] [PubMed]
2. Lim, H.; Devesa, S.S.; Sosa, J.A.; Check, D.; Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality
in the United States, 1974–2013. JAMA 2017, 317, 1338–1348. [CrossRef] [PubMed]
3. Kilfoy, B.A.; Zheng, T.; Holford, T.R.; Han, X.; Ward, M.H.; Sjodin, A.; Zhang, Y.; Bai, Y.; Zhu, C.;
Guo, G.L.; et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control
2009, 20, 525–531. [CrossRef] [PubMed]
4. Chen, A.Y.; Jemal, A.; Ward, E.M. Increasing incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer 2009, 115, 3801–3807. [CrossRef] [PubMed]
5. Carling, T.; Udelsman, R. Thyroid cancer. Ann. Rev. Med. 2014, 65, 125–137. [CrossRef] [PubMed]
6. Nilubol, N.; Zhang, L.; Kebebew, E. Multivariate analysis of the relationship between male sex, disease-specific
survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid
2013, 23, 695–702. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 3934 18 of 31
7. Butts, C.A.; Brady, J.J., III; Wilhelm, S.; Castor, L.; Sherwood, A.; McCall, A.; Patch, J.; Jones, P.; Cortes, V.;
Ong, A.W. Do simple beside lung function tests predict morbidity after rib fractures? Am. J. Surg.
2017, 213, 473–477. [CrossRef] [PubMed]
8. Besic, N.; Auersperg, M.; Us-Krasovec, M.; Golouh, R.; Frkovic-Grazio, S.; Vodnik, A. Effect of primary
treatment on survival in anaplastic thyroid carcinoma. Eur J. Surg Oncol. 2001, 27, 260–264. [CrossRef]
9. Molinaro, E.; Romei, C.; Biagini, A.; Sabini, E.; Agate, L.; Mazzeo, S.; Materazzi, G.; Sellari-Franceschini, S.;
Ribechini, A.; Torregrossa, L.; et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and
advanced therapies. Nat. Rev. Endocrinol. 2017, 13, 644–660. [CrossRef]
10. Smallridge, R.C.; Marlow, L.A.; Copland, J.A. Anaplastic thyroid cancer: Molecular pathogenesis and
emerging therapies. Endocr. Relat. Cancer 2009, 16, 17–44. [CrossRef]
11. Hadoux, J.; Pacini, F.; Tuttle, R.M.; Schlumberger, M. Management of advanced medullary thyroid cancer.
Lancet Diabetes Endocrinol. 2016, 4, 64–71. [CrossRef]
12. Fridman, W.H.; Zitvogel, L.; Sautes-Fridman, C.; Kroemer, G. The immune contexture in cancer prognosis
and treatment. Nat. Rev. Clin. Oncol. 2017, 14, 717–734. [CrossRef]
13. Cunha, L.L.; Marcello, M.A.; Ward, L.S. The role of the inflammatory microenvironment in thyroid
carcinogenesis. Endocr. Relat. Cancer 2014, 21, 85–103. [CrossRef]
14. Antonelli, A.; Ferrari, S.M.; Corrado, A.; Di Domenicantonio, A.; Fallahi, P. Autoimmune thyroid disorders.
Autoimmun. Rev. 2015, 14, 174–180. [CrossRef]
15. Suarez, H.G.; Du Villard, J.A.; Caillou, B.; Schlumberger, M.; Tubiana, M.; Parmentier, C.; Monier, R. Detection
of activated ras oncogenes in human thyroid carcinomas. Oncogene 1988, 2, 403–406.
16. Lemoine, N.R.; Mayall, E.S.; Wyllie, F.S.; Farr, C.J.; Hughes, D.; Padua, R.A.; Thurston, V.; Williams, E.D.;
Wynford-Thomas, D. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988, 48, 4459–4463.
17. Agrawal, N.; Akbani, R.; Aksoy, B.A.; Ally, A.; Arachchi, H.; Asa, S.L.; Auman, J.T.; Balasundaram, M.; Balu, S.;
Baylin, S.B.; et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159, 676–690.
[CrossRef]
18. Grieco, M.; Santoro, M.; Berlingieri, M.T.; Melillo, R.M.; Donghi, R.; Bongarzone, I.; Pierotti, M.A.;
Della Porta, G.; Fusco, A.; Vecchio, G. PTC is a novel rearranged form of the ret proto-oncogene and
is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60, 557–563. [CrossRef]
19. Pierotti, M.A.; Bongarzone, I.; Borrello, M.G.; Mariani, C.; Miranda, C.; Sozzi, G.; Greco, A. Rearrangements
of TRK proto-oncogene in papillary thyroid carcinomas. J. Endocrinol. Investig. 1995, 18, 130–133. [CrossRef]
20. Xing, M. BRAF mutation in thyroid cancer. Endocr.-Relat. Cancer 2005, 12, 245–262. [CrossRef]
21. Mulligan, L.M. RET revisited: Expanding the oncogenic portfolio. Nat. Rev. Cancer 2014, 14, 173–186.
[CrossRef]
22. Vanden Borre, P.; Schrock, A.B.; Anderson, P.M.; Morris, J.C., III; Heilmann, A.M.; Holmes, O.; Wang, K.;
Johnson, A.; Waguespack, S.G.; Ou, S.I.; et al. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma
Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist
2017, 22, 255–263. [CrossRef]
23. Rodrigues, R.F.; Roque, L.; Krug, T.; Leite, V. Poorly differentiated and anaplastic thyroid carcinomas:
Chromosomal and oligo-array profile of five new cell lines. Br. J. Cancer 2007, 96, 1237–1245. [CrossRef]
24. Basolo, F.; Pisaturo, F.; Pollina, L.E.; Fontanini, G.; Elisei, R.; Molinaro, E.; Iacconi, P.; Miccoli, P.; Pacini, F.
N-ras mutation in poorly differentiated thyroid carcinomas: Correlation with bone metastases and inverse
correlation to thyroglobulin expression. Thyroid 2000, 10, 19–23. [CrossRef]
25. Jung, S.H.; Kim, M.S.; Jung, C.K.; Park, H.C.; Kim, S.Y.; Liu, J.; Bae, J.S.; Lee, S.H.; Kim, T.M.; Chung, Y.J.
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular
carcinoma. Oncotarget 2016, 7, 69638–69648. [CrossRef]
26. Yoo, S.K.; Lee, S.; Kim, S.J.; Jee, H.G.; Kim, B.A.; Cho, H.; Song, Y.S.; Cho, S.W.; Won, J.K.; Shin, J.Y.; et al.
Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid
Cancers. PLoS Genet. 2016, 12, e1006239. [CrossRef]
27. Oliveira, G.; Polonia, A.; Cameselle-Teijeiro, J.M.; Leitao, D.; Sapia, S.; Sobrinho-Simoes, M.; Eloy, C. EWSR1
rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing
family tumor elements (CEFTE). Virchows Arch. 2017, 470, 517–525. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 19 of 31
28. Kabata, P.; Kaniuka-Jakubowska, S.; Kabata, W.; Lakomy, J.; Biernat, W.; Sworczak, K.; Jaskiewicz, J.;
Swierblewski, M. Primary Ewing Sarcoma of the Thyroid-Eight Cases in a Decade: A Case Report and
Literature Review. Front. Endocrinol. Lausanne 2017, 8, 257. [CrossRef]
29. Gane, E.J.; Pianko, S.; Roberts, S.K.; Thompson, A.J.; Zeuzem, S.; Zuckerman, E.; Ben-Ari, Z.; Foster, G.R.;
Agarwal, K.; Laursen, A.L.; et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus
uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis
infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): Two randomised,
phase 2, open-label trials. Lancet Gastroenterol. Hepatol. 2017, 2, 805–813.
30. Liu, R.; Xing, M. TERT promoter mutations in thyroid cancer. Endocr. Relat. Cancer 2016, 23, 143–155.
[CrossRef]
31. Caillou, B.; Talbot, M.; Weyemi, U.; Pioche-Durieu, C.; Al Ghuzlan, A.; Bidart, J.M.; Chouaib, S.;
Schlumberger, M.; Dupuy, C. Tumor-associated macrophages (TAMs) form an interconnected cellular
supportive network in anaplastic thyroid carcinoma. PLoS ONE 2011, 6, 22567. [CrossRef]
32. Ryder, M.; Ghossein, R.A.; Ricarte-Filho, J.C.; Knauf, J.A.; Fagin, J.A. Increased density of tumor-associated
macrophages is associated with decreased survival in advanced thyroid cancer. Endocr.-Relat. Cancer
2008, 15, 1069–1074. [CrossRef]
33. Matricardi, P.M.; Dramburg, S.; Alvarez-Perea, A.; Antolin-Amerigo, D.; Apfelbacher, C.;
Atanaskovic-Markovic, M.; Berger, U.; Blaiss, M.S.; Blank, S.; Boni, E.; et al. The Role of Mobile Health
Technologies in Allergy Care: An EAACI Position Paper. Allergy 2019. [CrossRef]
34. Landa, I.; Ibrahimpasic, T.; Boucai, L.; Sinha, R.; Knauf, J.A.; Shah, R.H.; Dogan, S.; Ricarte-Filho, J.C.;
Krishnamoorthy, G.P.; Xu, B.; et al. Genomic and transcriptomic hallmarks of poorly differentiated and
anaplastic thyroid cancers. J. Clin. Investig. 2016, 126, 1052–1066. [CrossRef]
35. Kunstman, J.W.; Juhlin, C.C.; Goh, G.; Brown, T.C.; Stenman, A.; Healy, J.M.; Rubinstein, J.C.; Choi, M.;
Kiss, N.; Nelson-Williams, C. Characterization of the mutational landscape of anaplastic thyroid cancer via
whole-exome sequencing. Hum. Mol. Genet. 2015, 24, 2318–2329. [CrossRef]
36. Jeon, M.J.; Chun, S.M.; Kim, D.; Kwon, H.; Jang, E.K.; Kim, T.Y.; Kim, W.B.; Shong, Y.K.; Jang, S.J.;
Song, D.E.; et al. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive
Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. Thyroid 2016, 26, 683–690. [CrossRef]
37. Kelly, L.M.; Barila, G.; Liu, P.; Evdokimova, V.N.; Trivedi, S.; Panebianco, F.; Gandhi, M.; Carty, S.E.;
Hodak, S.P.; Luo, J.; et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic
target in the aggressive forms of thyroid cancer. Proc. Natl. Acad. Sci. USA 2014, 111, 4233–4238. [CrossRef]
38. Arndt, A.; Steinestel, K.; Rump, A.; Sroya, M.; Bogdanova, T.; Kovgan, L.; Port, M.; Abend, M.; Eder, S.
Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid
carcinoma after the Chernobyl accident. J. Pathol. Clin. Res. 2018, 4, 175–183. [CrossRef]
39. Nikiforova, M.N.; Nikitski, A.V.; Panebianco, F.; Kaya, C.; Yip, L.; Williams, M.; Chiosea, S.I.; Seethala, R.R.;
Roy, S.; Condello, V.; et al. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of
the Thyroid Gland. Thyroid 2019, 29, 161–173. [CrossRef]
40. Weetman, A.P.; Bennett, G.L.; Wong, W.L. Thyroid follicular cells produce interleukin-8. J. Clin. Endocrinol. Metab.
1992, 75, 328–330.
41. Kammoun-Krichen, M.; Bougacha-Elleuch, N.; Mnif, M.; Bougacha, F.; Charffedine, I.; Rebuffat, S.; Rebai, A.;
Glasson, E.; Abid, M.; Ayadi, F.; et al. IL-1beta a potential factor for discriminating between thyroid carcinoma
and atrophic thyroiditis. Eur. Cytokine Netw. 2012, 23, 101–106.
42. Varricchi, G.; Harker, J.; Borriello, F.; Marone, G.; Durham, S.R.; Shamji, M.H. T follicular helper (Tfh) cells in
normal immune responses and in allergic disorders. Allergy 2016, 71, 1086–1094. [CrossRef]
43. Bacher, P.; Scheffold, A. The effect of regulatory T cells on tolerance to airborne allergens and allergen
immunotherapy. J. Allergy Clin. Immunol. 2018, 142, 1697–1709. [CrossRef]
44. Mantovani, A.; Biswas, S.K.; Galdiero, M.R.; Sica, A.; Locati, M. Macrophage plasticity and polarization in
tissue repair and remodelling. J. Pathol. 2013, 229, 176–185. [CrossRef]
45. Ryder, M.; Gild, M.; Hohl, T.M.; Pamer, E.; Knauf, J.; Ghossein, R.; Joyce, J.A.; Fagin, J.A. Genetic
and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs
BRAF-induced thyroid cancer progression. PLoS ONE 2013, 8, e54302. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 20 of 31
46. Ameziane-El-Hassani, R.; Talbot, M.; de Souza Dos Santos, M.C.; Al Ghuzlan, A.; Hartl, D.; Bidart, J.M.;
De Deken, X.; Miot, F.; Diallo, I.; de Vathaire, F.; et al. NADPH oxidase DUOX1 promotes long-term persistence
of oxidative stress after an exposure to irradiation. Proc. Natl. Acad. Sci. USA 2015, 112, 5051–5056. [CrossRef]
47. Melillo, R.M.; Guarino, V.; Avilla, E.; Galdiero, M.R.; Liotti, F.; Prevete, N.; Rossi, F.W.; Basolo, F.;
Ugolini, C.; de Paulis, A.; et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene
2010, 29, 6203–6215. [CrossRef]
48. Visciano, C.; Liotti, F.; Prevete, N.; Cali, G.; Franco, R.; Collina, F.; de Paulis, A.; Marone, G.; Santoro, M.;
Melillo, R.M. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid
cancer cells through an IL-8-Akt-Slug pathway. Oncogene 2015, 34, 5175–5186. [CrossRef]
49. Martins, M.B.; Marcello, M.A.; Batista, F.A.; Peres, K.C.; Meneghetti, M.; Ward, M.A.L.; Etchebehere, E.;
da Assumpcao, L.V.M.; Ward, L.S. Serum interleukin measurement may help identify thyroid cancer patients
with active disease. Clin. Biochem. 2018, 52, 1–7. [CrossRef]
50. Warakomski, J.; Romuk, E.; Jarzab, B.; Krajewska, J.; Sieminska, L. Concentrations of Selected Adipokines,
Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer
Stages. Int. J. Endocrinol. 2018, 2018, 4921803. [CrossRef]
51. Sloot, Y.J.E.; Rabold, K.; Netea, M.G.; Smit, J.W.A.; Hoogerbrugge, N.; Netea-Maier, R.T. Effect of PTEN
inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages
in patients with PTEN hamartoma tumor syndrome. Oncogene 2019, 38, 3743. [CrossRef]
52. Li, C.; Li, H.; Jiang, K.; Li, J.; Gai, X. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the
expression of TGF-beta1 and IL-10 and tumor cells migration. Biomed. Mater. Eng. 2014, 24, 869–875.
53. Yu, H.; Huang, X.; Liu, X.; Jin, H.; Zhang, G.; Zhang, Q.; Yu, J. Regulatory T cells and plasmacytoid dendritic
cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic
goiter. Endocrine 2013, 44, 172–181. [CrossRef]
54. Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; Bini, M.; Perez Alea, M.; Maria Florena, A.; Miceli, L.; Condorelli, G.;
Bonventre, S.; Di Gesu, G.; et al. Autocrine production of interleukin-4 and interleukin-10 is required for
survival and growth of thyroid cancer cells. Cancer Res. 2006, 66, 1491–1499. [CrossRef]
55. Stassi, G.; Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; Di Liberto, D.; Patti, M.; Florena, A.; Di Gaudio, F.;
Di Gesu, G.; De Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of
interleukin-4 and interleukin-10. Cancer Res. 2003, 63, 6784–6790.
56. Stanciu, A.E.; Serdarevic, N.; Hurduc, A.E.; Stanciu, M.M. IL-4, IL-10 and high sensitivity-CRP as potential
serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto’s
thyroiditis. Scand. J. Clin. Lab. Investig. 2015, 75, 539–548. [CrossRef]
57. Cunha, L.L.; Morari, E.C.; Nonogaki, S.; Marcello, M.A.; Soares, F.A.; Vassallo, J.; Ward, L.S.
Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer.
Cancer Immunol. Immunother. 2017, 66, 141–148. [CrossRef]
58. Wang, X.; Li, J.; Lu, C.; Wang, G.; Wang, Z.; Liu, X.; Liu, B.; Zhang, Q.; Yang, Q. IL-10-producing B cells
in differentiated thyroid cancer suppress the effector function of T cells but improve their survival upon
activation. Exp. Cell Res. 2019, 376, 192–197. [CrossRef]
59. Lu, X. Impact of IL-12 in Cancer. Curr. Cancer Drug Targets 2017, 17, 682–697. [CrossRef]
60. Shi, Y.; Parhar, R.S.; Zou, M.; Baitei, E.; Kessie, G.; Farid, N.R.; Alzahrani, A.; Al-Mohanna, F.A. Gene
therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein. Hum. Gene Ther.
2003, 14, 1741–1751. [CrossRef]
61. Parhar, R.S.; Zou, M.; Al-Mohanna, F.A.; Baitei, E.Y.; Assiri, A.M.; Meyer, B.F.; Shi, Y. IL-12 immunotherapy
of Braf(V600E)-induced papillary thyroid cancer in a mouse model. Lab. Investig. 2016, 96, 89–97. [CrossRef]
62. Jiang, G.; Ma, S.; Wei, Y.; Wu, Y.; Yu, X.; Liu, H. The prevalence and distribution of Th17 and Tc17 cells in
patients with thyroid tumor. Immunol. Lett. 2014, 162, 68–73. [CrossRef]
63. Bailey, S.R.; Nelson, M.H.; Himes, R.A.; Li, Z.; Mehrotra, S.; Paulos, C.M. Th17 cells in cancer: The ultimate
identity crisis. Front. Immunol. 2014, 5, 276. [CrossRef]
64. Lu, Y.; Yuan, Y. Serum level of interleukin-17 and interleukin-35 as a biomarker for diagnosis of thyroid
cancer. J. Cancer Res. Ther. 2015, 11, 209–211. [CrossRef]
65. Lee, Y.C.; Chung, J.H.; Kim, S.K.; Rhee, S.Y.; Chon, S.; Oh, S.J.; Hong, I.K.; Eun, Y.G. Association between
interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population.
Cytokine 2015, 71, 283–288. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 21 of 31
66. Zhang, L.; Chen, J.; Xu, C.; Qi, L.; Ren, Y. Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells
of patients with differentiated thyroid carcinoma. Exp. Ther. Med. 2018, 15, 2661–2666. [CrossRef]
67. Carvalho, D.F.G.; Zanetti, B.R.; Miranda, L.; Hassumi-Fukasawa, M.K.; Miranda-Camargo, F.; Crispim, J.C.O.;
Soares, E.G. High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol. Lett.
2017, 13, 1925–1931. [CrossRef]
68. Crotty, S. A brief history of T cell help to B cells. Nat. Rev. Immunol. 2015, 15, 185–189. [CrossRef]
69. Xiao, M.; Hu, S.; Tang, J.; Zhang, L.; Jiang, H. Interleukin (IL)-21 promoter polymorphism increases the risk
of thyroid cancer in Chinese population. Gene 2014, 537, 15–19. [CrossRef]
70. Shinohara, S.; Rothstein, J.L. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine
growth factor for epithelial cells. Oncogene 2004, 23, 7571–7579. [CrossRef]
71. Knauf, J.A.; Sartor, M.A.; Medvedovic, M.; Lundsmith, E.; Ryder, M.; Salzano, M.; Nikiforov, Y.E.;
Giordano, T.J.; Ghossein, R.A.; Fagin, J.A. Progression of BRAF-induced thyroid cancer is associated
with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene
2011, 30, 3153–3162. [CrossRef]
72. Eloy, C.; Santos, J.; Cameselle-Teijeiro, J.; Soares, P.; Sobrinho-Simoes, M. TGF-beta/Smad pathway and BRAF
mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch.
2012, 460, 587–600. [CrossRef]
73. Ivanova, K.; Manolova, I.; Ignatova, M.M.; Gulubova, M. Immunohistochemical Expression of TGF-Beta1,
SMAD4, SMAD7, TGFbetaRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. Open Access
Maced. J. Med. Sci. 2018, 6, 435–441. [CrossRef]
74. Brace, M.D.; Wang, J.; Petten, M.; Bullock, M.J.; Makki, F.; Trites, J.; Taylor, S.M.; Hart, R.D. Differential
expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential
diagnostic tool? J. Otolaryngol. Head Neck Surg. 2014, 43, 22. [CrossRef]
75. Zhang, K.; Liu, X.; Hao, F.; Dong, A.; Chen, D. Targeting TGF-beta1 inhibits invasion of anaplastic thyroid
carcinoma cell through SMAD2-dependent S100A4-MMP-2/9 signalling. Am. J. Transl. Res. 2016, 8, 2196.
76. Zitvogel, L.; Galluzzi, L.; Kepp, O.; Smyth, M.J.; Kroemer, G. Type I interferons in anticancer immunity.
Nat. Rev. Immunol. 2015, 15, 405–414. [CrossRef]
77. Angell, T.E.; Lechner, M.G.; Jang, J.K.; Correa, A.J.; LoPresti, J.S.; Epstein, A.L. BRAF V600E in papillary
thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive
immune cell infiltration. Thyroid 2014, 24, 1385–1393. [CrossRef]
78. Lv, N.; Gao, Y.; Guan, H.; Wu, D.; Ding, S.; Teng, W.; Shan, Z. Inflammatory mediators, tumor necrosis
factor-alpha and interferon-gamma, induce EMT in human PTC cell lines. Oncol. Lett. 2015, 10, 2591–2597.
[CrossRef]
79. Rotondi, M.; Coperchini, F.; Awwad, O.; Pignatti, P.; Di Buduo, C.A.; Abbonante, V.; Magri, F.; Balduini, A.;
Chiovato, L. Effect of Interferon-gamma on the Basal and the TNFalpha-Stimulated Secretion of CXCL8
in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
Mediat. Inflamm. 2016, 2016, 8512417. [CrossRef]
80. Bosisio, D.; Ronca, R.; Salvi, V.; Presta, M.; Sozzani, S. Dendritic cells in inflammatory angiogenesis and
lymphangiogenesis. Curr. Opin. Immunol. 2018, 53, 180–186. [CrossRef]
81. Melillo, R.M.; Castellone, M.D.; Guarino, V.; De Falco, V.; Cirafici, A.M.; Salvatore, G.; Caiazzo, F.; Basolo, F.;
Giannini, R.; Kruhoffer, M.; et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and
mitogenic phenotype of thyroid cancer cells. J. Clin. Investig. 2005, 115, 1068–1081. [CrossRef]
82. Borrello, M.G.; Alberti, L.; Fischer, A.; Degl’innocenti, D.; Ferrario, C.; Gariboldi, M.; Marchesi, F.; Allavena, P.;
Greco, A.; Collini, P.; et al. Induction of a proinflammatory program in normal human thyrocytes by the
RET/PTC1 oncogene. Proc. Natl. Acad. Sci. USA 2005, 102, 14825–14830. [CrossRef]
83. Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Piaggi, S.; Di Domenicantonio, A.; Galleri, D.; Santarpia, L.; Basolo, F.;
Ferrannini, E.; Miccoli, P. Variable modulation by cytokines and thiazolidinediones of the prototype Th1
chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 2012, 59, 218–222. [CrossRef]
84. Rotondi, M.; Coperchini, F.; Latrofa, F.; Chiovato, L. Role of Chemokines in Thyroid Cancer Microenvironment:
Is CXCL8 the Main Player? Front. Endocrinol. Lausanne 2018, 9, 314. [CrossRef]
85. Rotondi, M.; Coperchini, F.; Pignatti, P.; Magri, F.; Chiovato, L. Metformin reverts the secretion of CXCL8
induced by TNF-alpha in primary cultures of human thyroid cells: An additional indirect anti-tumor effect
of the drug. J. Clin. Endocrinol. Metab. 2015, 100, 427–432. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 22 of 31
86. Muzza, M.; Degl’Innocenti, D.; Colombo, C.; Perrino, M.; Ravasi, E.; Rossi, S.; Cirello, V.; Beck-Peccoz, P.;
Borrello, M.G.; Fugazzola, L. The tight relationship between papillary thyroid cancer, autoimmunity and
inflammation: Clinical and molecular studies. Clin. Endocrinol. Oxf. 2010, 72, 702–708. [CrossRef]
87. Bauerle, K.T.; Schweppe, R.E.; Lund, G.; Kotnis, G.; Deep, G.; Agarwal, R.; Pozdeyev, N.; Wood, W.M.;
Haugen, B.R. Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model
of thyroid cancer is associated with secreted interleukin-8. J. Clin. Endocrinol. Metab. 2014, 99, 1436–1444.
[CrossRef]
88. Fang, W.; Ye, L.; Shen, L.; Cai, J.; Huang, F.; Wei, Q.; Fei, X.; Chen, X.; Guan, H.; Wang, W.; et al.
Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing
CXCL8. Carcinogenesis 2014, 35, 1780–1787. [CrossRef]
89. Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Frascerra, S.; Piaggi, S.; Gelmini, S.; Lupi, C.; Minuto, M.; Berti, P.;
Benvenga, S.; et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid
cancer: Modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr. Relat. Cancer
2009, 16, 1299–1311. [CrossRef]
90. Liu, Z.; Sun, D.X.; Teng, X.Y.; Xu, W.X.; Meng, X.P.; Wang, B.S. Expression of stromal cell-derived factor 1 and
CXCR7 in papillary thyroid carcinoma. Endocr. Pathol. 2012, 23, 247–253. [CrossRef]
91. Liu, Z.; Yang, L.; Teng, X.; Zhang, H.; Guan, H. The involvement of CXCR7 in modulating the progression of
papillary thyroid carcinoma. J. Surg. Res. 2014, 191, 379–388. [CrossRef]
92. Zeng, W.; Chang, H.; Ma, M.; Li, Y. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells
via NF-kappa B signaling-induced MMP-3 production. Exp. Mol. Pathol. 2014, 97, 184–190. [CrossRef]
93. Urra, S.; Fischer, M.C.; Martinez, J.R.; Veliz, L.; Orellana, P.; Solar, A.; Bohmwald, K.; Kalergis, A.; Riedel, C.;
Corvalan, A.H.; et al. Differential expression profile of CXCR3 splicing variants is associated with thyroid
neoplasia. Potential role in papillary thyroid carcinoma oncogenesis? Oncotarget 2018, 9, 2445–2467.
[CrossRef]
94. Loffredo, S.; Staiano, R.I.; Granata, F.; Genovese, A.; Marone, G. Immune cells as a source and target of
angiogenic and lymphangiogenic factors. Chem. Immunol. Allergy 2014, 99, 15–36.
95. Varricchi, G.; Raap, U.; Rivellese, F.; Marone, G.; Gibbs, B.F. Human mast cells and basophils-How are they
similar how are they different? Immunol. Rev. 2018, 282, 8–34. [CrossRef]
96. Varricchi, G.; Loffredo, S.; Galdiero, M.R.; Marone, G.; Cristinziano, L.; Granata, F. Innate effector cells in
angiogenesis and lymphangiogenesis. Curr. Opin. Immunol. 2018, 53, 152–160. [CrossRef]
97. Detoraki, A.; Staiano, R.I.; Granata, F.; Giannattasio, G.; Prevete, N.; de Paulis, A.; Ribatti, D.; Genovese, A.;
Triggiani, M.; Marone, G. Vascular endothelial growth factors synthesized by human lung mast cells exert
angiogenic effects. J. Allergy Clin. Immunol. 2009, 123, 1142–1149. [CrossRef]
98. Granata, F.; Frattini, A.; Loffredo, S.; Staiano, R.I.; Petraroli, A.; Ribatti, D.; Oslund, R.; Gelb, M.H.;
Lambeau, G.; Marone, G. Production of vascular endothelial growth factors from human lung macrophages
induced by group IIA and group X secreted phospholipases A2. J. Immunol. 2010, 184, 5232–5241. [CrossRef]
99. Bruno, A.; Focaccetti, C.; Pagani, A.; Imperatori, A.S.; Spagnoletti, M.; Rotolo, N.; Cantelmo, A.R.; Franzi, F.;
Capella, C.; Ferlazzo, G.; et al. The proangiogenic phenotype of natural killer cells in patients with non-small
cell lung cancer. Neoplasia 2013, 15, 133–142. [CrossRef]
100. Curiel, T.J.; Cheng, P.; Mottram, P.; Alvarez, X.; Moons, L.; Evdemon-Hogan, M.; Wei, S.; Zou, L.; Kryczek, I.;
Hoyle, G.; et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res.
2004, 64, 5535–5538. [CrossRef]
101. Nissim Ben Efraim, A.H.; Levi-Schaffer, F. Roles of eosinophils in the modulation of angiogenesis.
Chem. Immunol. Allergy 2014, 99, 138–154.
102. Varricchi, G.; Galdiero, M.R.; Loffredo, S.; Lucarini, V.; Marone, G.; Mattei, F.; Schiavoni, G. Eosinophils:
The unsung heroes in cancer? Oncoimmunology 2018, 7, e1393134. [CrossRef]
103. Shiraishi, J.; Koyama, H.; Seki, M.; Hatayama, M.; Naka, M.; Kurajoh, M.; Okazaki, H.; Shoji, T.; Moriwaki, Y.;
Yamamoto, T.; et al. Anaplastic thyroid carcinoma accompanied by uncontrollable eosinophilia. Int. Med.
2015, 54, 611–616. [CrossRef]
104. Facciabene, A.; Peng, X.; Hagemann, I.S.; Balint, K.; Barchetti, A.; Wang, L.P.; Gimotty, P.A.; Gilks, C.B.; Lal, P.;
Zhang, L.; et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature
2011, 475, 226–230. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 23 of 31
105. Murdoch, C.; Muthana, M.; Coffelt, S.B.; Lewis, C.E. The role of myeloid cells in the promotion of tumour
angiogenesis. Nat. Rev. Cancer 2008, 8, 618–631. [CrossRef]
106. Loffredo, S.; Borriello, F.; Iannone, R.; Ferrara, A.L.; Galdiero, M.R.; Gigantino, V.; Esposito, P.; Varricchi, G.;
Lambeau, G.; Cassatella, M.A.; et al. Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic
and Antiangiogenic Factors by Human Neutrophils. Front. Immunol. 2017, 8, 443. [CrossRef]
107. Galdiero, M.R.; Varricchi, G.; Loffredo, S.; Mantovani, A.; Marone, G. Roles of neutrophils in cancer growth
and progression. J. Leukoc. Biol. 2018, 103, 457–464. [CrossRef]
108. Carretero, R.; Sektioglu, I.M.; Garbi, N.; Salgado, O.C.; Beckhove, P.; Hammerling, G.J. Eosinophils orchestrate
cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat. Immunol.
2015, 16, 609–617. [CrossRef]
109. Lucarini, V.; Ziccheddu, G.; Macchia, I.; La Sorsa, V.; Peschiaroli, F.; Buccione, C.; Sistigu, A.; Sanchez, M.;
Andreone, S.; D’Urso, M.T.; et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in
melanoma-bearing mice through eosinophils. Oncoimmunology 2017, 6, e1317420. [CrossRef]
110. Galdiero, M.R.; Varricchi, G.; Marone, G. The immune network in thyroid cancer. Oncoimmunology
2016, 5, e1168556. [CrossRef]
111. Bissell, M.J.; Hines, W.C. Why don’t we get more cancer? A proposed role of the microenvironment in
restraining cancer progression. Nat. Med. 2011, 17, 320–329. [CrossRef]
112. Coussens, L.M.; Zitvogel, L.; Palucka, A.K. Neutralizing tumor-promoting chronic inflammation: A magic
bullet? Science 2013, 339, 286–291. [CrossRef]
113. Galdiero, M.R.; Garlanda, C.; Jaillon, S.; Marone, G.; Mantovani, A. Tumor associated macrophages and
neutrophils in tumor progression. J. Cell Physiol. 2013, 228, 1404–1412. [CrossRef]
114. Flavell, R.A.; Sanjabi, S.; Wrzesinski, S.H.; Licona-Limon, P. The polarization of immune cells in the tumour
environment by TGFbeta. Nat. Rev. Immunol. 2010, 10, 554–567. [CrossRef]
115. Schiavoni, G.; Gabriele, L.; Mattei, F. The tumor microenvironment: A pitch for multiple players. Front. Oncol.
2013, 3, 90. [CrossRef]
116. Chevrier, S.; Levine, J.H.; Zanotelli, V.R.T.; Silina, K.; Schulz, D.; Bacac, M.; Ries, C.H.; Ailles, L.; Jewett, M.A.S.;
Moch, H.; et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell 2017, 169, 736–749. [CrossRef]
117. Dick, S.A.; Macklin, J.A.; Nejat, S.; Momen, A.; Clemente-Casares, X.; Althagafi, M.G.; Chen, J.; Kantores, C.;
Hosseinzadeh, S.; Aronoff, L.; et al. Self-renewing resident cardiac macrophages limit adverse remodeling
following myocardial infarction. Nat. Immunol. 2019, 20, 29–39. [CrossRef]
118. Kim, S.; Cho, S.W.; Min, H.S.; Kim, K.M.; Yeom, G.J.; Kim, E.Y.; Lee, K.E.; Yun, Y.G.; Park, D.J.; Park, Y.J.
The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol. Metab. Seoul
2013, 28, 192–198. [CrossRef]
119. Chang, W.C.; Chen, J.Y.; Lee, C.H.; Yang, A.H. Expression of decoy receptor 3 in diffuse sclerosing variant
of papillary thyroid carcinoma: Correlation with M2 macrophage differentiation and lymphatic invasion.
Thyroid 2013, 23, 720–726. [CrossRef]
120. Na, K.J.; Choi, H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications.
Endocr. Relat. Cancer 2018, 25, 523–531. [CrossRef]
121. Cho, J.W.; Kim, W.W.; Lee, Y.M.; Jeon, M.J.; Kim, W.G.; Song, D.E.; Park, Y.; Chung, K.W.; Hong, S.J.; Sung, T.Y.
Impact of tumor-associated macrophages and BRAF(V600E) mutation on clinical outcomes in patients with
various thyroid cancers. Head Neck 2019, 41, 686–691. [CrossRef]
122. Qing, W.; Fang, W.Y.; Ye, L.; Shen, L.Y.; Zhang, X.F.; Fei, X.C.; Chen, X.; Wang, W.Q.; Li, X.Y.; Xiao, J.C.; et al.
Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid
carcinoma. Thyroid 2012, 22, 905–910. [CrossRef]
123. Jung, K.Y.; Cho, S.W.; Kim, Y.A.; Kim, D.; Oh, B.C.; Park, D.J.; Park, Y.J. Cancers with Higher Density
of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J. Pathol. Transl. Med.
2015, 49, 318–324. [CrossRef]
124. Li, X.J.; Gangadaran, P.; Kalimuthu, S.; Oh, J.M.; Zhu, L.; Jeong, S.Y.; Lee, S.W.; Lee, J.; Ahn, B.C. Role
of pulmonary macrophages in initiation of lung metastasis in anaplastic thyroid cancer. Int. J. Cancer
2016, 139, 2583–2592. [CrossRef]
125. Zhang, R.; Hardin, H.; Chen, J.; Guo, Z.; Lloyd, R.V. Non-Coding RNAs in Thyroid Cancer. Endocr. Pathol.
2016, 27, 12–20. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 24 of 31
126. Huang, J.K.; Ma, L.; Song, W.H.; Lu, B.Y.; Huang, Y.B.; Dong, H.M.; Ma, X.K.; Zhu, Z.Z.; Zhou, R.
LncRNA-MALAT1 Promotes Angiogenesis of Thyroid Cancer by Modulating Tumor-Associated Macrophage
FGF2 Protein Secretion. J. Cell Biochem. 2017, 118, 4821–4830. [CrossRef]
127. Arts, R.J.; Plantinga, T.S.; Tuit, S.; Ulas, T.; Heinhuis, B.; Tesselaar, M.; Sloot, Y.; Adema, G.J.; Joosten, L.A.;
Smit, J.W.; et al. Transcriptional and metabolic reprogramming induce an inflammatory phenotype in
non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology 2016, 5, e1229725. [CrossRef]
128. Zhang, L.J.; Xiong, Y.; Nilubol, N.; He, M.; Bommareddi, S.; Zhu, X.; Jia, L.; Xiao, Z.; Park, J.W.; Xu, X.
Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity.
Carcinogenesis 2015, 36, 420–428. [CrossRef]
129. Dudek, A.M.; Martin, S.; Garg, A.D.; Agostinis, P. Immature, Semi-Mature, and Fully Mature Dendritic Cells:
Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front. Immunol. 2013, 4, 438.
[CrossRef]
130. Hilly, O.; Koren, R.; Raz, R.; Rath-Wolfson, L.; Mizrachi, A.; Hamzany, Y.; Bachar, G.; Shpitzer, T. The role
of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. Am. J. Clin. Pathol.
2013, 139, 87–92. [CrossRef]
131. Scarpino, S.; Stoppacciaro, A.; Ballerini, F.; Marchesi, M.; Prat, M.; Stella, M.C.; Sozzani, S.; Allavena, P.;
Mantovani, A.; Ruco, L.P. Papillary carcinoma of the thyroid: Hepatocyte growth factor (HGF) stimulates
tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156, 831–837.
[CrossRef]
132. Tsuge, K.; Takeda, H.; Kawada, S.; Maeda, K.; Yamakawa, M. Characterization of dendritic cells in
differentiated thyroid cancer. J. Pathol. 2005, 205, 565–576. [CrossRef]
133. Ugolini, C.; Basolo, F.; Proietti, A.; Vitti, P.; Elisei, R.; Miccoli, P.; Toniolo, A. Lymphocyte and immature
dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma.
Thyroid 2007, 17, 389–393. [CrossRef]
134. Marone, G.; Varricchi, G.; Loffredo, S.; Granata, F. Mast cells and basophils in inflammatory and tumor
angiogenesis and lymphangiogenesis. Eur J. Pharmacol. 2016, 778, 146–151. [CrossRef]
135. Varricchi, G.; Galdiero, M.R.; Loffredo, S.; Marone, G.; Iannone, R.; Granata, F. Are Mast Cells MASTers in
Cancer? Front. Immunol. 2017, 8, 424. [CrossRef]
136. Varricchi, G.; Galdiero, M.R.; Marone, G.; Granata, F.; Borriello, F. Controversial role of mast cells in skin
cancers. Exp. Dermatol. 2017, 26, 11–17. [CrossRef]
137. Ribatti, D.; Vacca, A.; Ria, R.; Marzullo, A.; Nico, B.; Filotico, R.; Roncali, L.; Dammacco, F. Neovascularisation,
expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with
pathological progression in human malignant melanoma. Eur. J. Cancer 2003, 39, 666–674. [CrossRef]
138. Johnson, C.; Huynh, V.; Hargrove, L.; Kennedy, L.; Graf-Eaton, A.; Owens, J.; Trzeciakowski, J.P.;
Hodges, K.; DeMorrow, S.; Han, Y.; et al. Inhibition of Mast Cell-Derived Histamine Decreases Human
Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling. Am. J. Pathol.
2016, 186, 123–133. [CrossRef]
139. Pittoni, P.; Tripodo, C.; Piconese, S.; Mauri, G.; Parenza, M.; Rigoni, A.; Sangaletti, S.; Colombo, M.P. Mast cell
targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant
neuroendocrine cancers. Cancer Res. 2011, 71, 5987–5997. [CrossRef]
140. Giannou, A.D.; Marazioti, A.; Spella, M.; Kanellakis, N.I.; Apostolopoulou, H.; Psallidas, I.; Prijovich, Z.M.;
Vreka, M.; Zazara, D.E.; Lilis, I.; et al. Mast cells mediate malignant pleural effusion formation. J. Clin. Investig.
2015, 125, 2317–2334. [CrossRef]
141. Siiskonen, H.; Poukka, M.; Bykachev, A.; Tyynela-Korhonen, K.; Sironen, R.; Pasonen-Seppanen, S.;
Harvima, I.T. Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and
advanced tumor stage in melanoma. Melanoma Res. 2015, 25, 479–485. [CrossRef]
142. Sammarco, G.; Varricchi, G.; Ferraro, V.; Ammendola, M.; De Fazio, M.; Altomare, D.F.; Luposella, M.;
Maltese, L.; Curro, G.; Marone, G.; et al. Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric
Cancer. Int. J. Mol. Sci. 2019, 20, 2106. [CrossRef]
143. Varricchi, G.; Pecoraro, A.; Marone, G.; Criscuolo, G.; Spadaro, G.; Genovese, A. Thymic Stromal
Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front. Immunol. 2018, 9, 1595. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 25 of 31
144. Ribatti, D.; Vacca, A.; Nico, B.; Quondamatteo, F.; Ria, R.; Minischetti, M.; Marzullo, A.; Herken, R.; Roncali, L.;
Dammacco, F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of
human multiple myeloma. Br. J. Cancer 1999, 79, 451–455. [CrossRef]
145. Proietti, A.; Ugolini, C.; Melillo, R.M.; Crisman, G.; Elisei, R.; Santoro, M.; Minuto, M.; Vitti, P.; Miccoli, P.;
Basolo, F. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary
thyroid carcinoma compared to adenomas: Correlation with clinical and pathological parameters. Thyroid
2011, 21, 1209–1215. [CrossRef]
146. Detoraki, A.; Granata, F.; Staibano, S.; Rossi, F.W.; Marone, G.; Genovese, A. Angiogenesis and
lymphangiogenesis in bronchial asthma. Allergy 2010, 65, 946–958. [CrossRef]
147. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428.
[CrossRef]
148. Aran, D.; Looney, A.P.; Liu, L.; Wu, E.; Fong, V.; Hsu, A.; Chak, S.; Naikawadi, R.P.; Wolters, P.J.;
Abate, A.R.; et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic
macrophage. Nat. Immunol. 2019, 20, 163–172. [CrossRef]
149. Gentek, R.; Ghigo, C.; Hoeffel, G.; Bulle, M.J.; Msallam, R.; Gautier, G.; Launay, P.; Chen, J.; Ginhoux, F.;
Bajenoff, M. Hemogenic Endothelial Fate Mapping Reveals Dual Developmental Origin of Mast Cells.
Immunity 2018, 48, 1160–1171. [CrossRef]
150. Li, Z.; Liu, S.; Xu, J.; Zhang, X.; Han, D.; Liu, J.; Xia, M.; Yi, L.; Shen, Q.; Xu, S. Adult Connective Tissue-Resident
Mast Cells Originate from Late Erythro-Myeloid Progenitors. Immunity 2018, 49, 640–653. [CrossRef]
151. Jaillon, S.; Galdiero, M.R.; Del Prete, D.; Cassatella, M.A.; Garlanda, C.; Mantovani, A. Neutrophils in innate
and adaptive immunity. Semin. Immunopathol. 2013, 35, 377–394. [CrossRef]
152. Sionov, R.V.; Fridlender, Z.G.; Granot, Z. The Multifaceted Roles Neutrophils Play in the Tumor
Microenvironment. Cancer Microenviron. 2015, 8, 125–158. [CrossRef]
153. Bhatti, I.; Peacock, O.; Lloyd, G.; Larvin, M.; Hall, R.I. Preoperative hematologic markers as independent
predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte versus
platelet-lymphocyte ratio. Am. J. Surg. 2010, 200, 197–203. [CrossRef]
154. Liu, C.L.; Lee, J.J.; Liu, T.P.; Chang, Y.C.; Hsu, Y.C.; Cheng, S.P. Blood neutrophil-to-lymphocyte ratio
correlates with tumor size in patients with differentiated thyroid cancer. J. Surg Oncol. 2013, 107, 493–497.
[CrossRef]
155. Seretis, C.; Gourgiotis, S.; Gemenetzis, G.; Seretis, F.; Lagoudianakis, E.; Dimitrakopoulos, G. The significance
of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal
goiters: A pilot study. Am. J. Surg. 2013, 205, 691–696. [CrossRef]
156. Lang, B.H.; Ng, C.P.; Au, K.B.; Wong, K.P.; Wong, K.K.; Wan, K.Y. Does preoperative neutrophil lymphocyte
ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?
World J. Surg. 2014, 38, 2605–2612. [CrossRef]
157. Cho, M.J.; Park, K.S.; Yoo, Y.B.; Yang, J.H. A comparative analysis of endoscopic thyroidectomy versus
conventional thyroidectomy in clinically lymph node negative thyroid cancer. Ann. Surg Treat. Res.
2015, 88, 69–76. [CrossRef]
158. Liu, J.F.; Ba, L.; Lv, H.; Lv, D.; Du, J.T.; Jing, X.M.; Yang, N.J.; Wang, S.X.; Li, C.; Li, X.X. Association between
neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: A meta-analysis. Sci. Rep. 2016, 6, 38551.
[CrossRef]
159. Kim, S.M.; Kim, E.H.; Kim, B.H.; Kim, J.H.; Park, S.B.; Nam, Y.J.; Ahn, K.H.; Oh, M.Y.; Kim, W.J.; Jeon, Y.K.;
et al. Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte
Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer.
Endocrinol. Metab. Seoul 2015, 30, 494–501. [CrossRef]
160. Machairas, N.; Kostakis, I.D.; Prodromidou, A.; Stamopoulos, P.; Feretis, T.; Garoufalia, Z.; Damaskos, C.;
Tsourouflis, G.; Kouraklis, G. Trends in white blood cell and platelet indices in a comparison of patients with
papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions.
Endocr. Res. 2017, 42, 311–317. [CrossRef]
161. Gong, W.; Yang, S.; Yang, X.; Guo, F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with
TNM stage in patients with papillary thyroid cancer. Clin. Sao Paulo 2016, 71, 311–314. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 26 of 31
162. Ozmen, S.; Timur, O.; Calik, I.; Altinkaynak, K.; Simsek, E.; Gozcu, H.; Arslan, A.; Carlioglu, A.
Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive
protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr. Regul. 2017, 51, 131–136.
[CrossRef]
163. Lee, F.; Yang, P.S.; Chien, M.N.; Lee, J.J.; Leung, C.H.; Cheng, S.P. An Increased Neutrophil-to-Lymphocyte
Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer. Int. J. Med. Sci.
2018, 15, 1757–1763. [CrossRef]
164. Xu, N.; Jian, Y.; Wang, Y.; Tian, W. Evaluation of neutrophil-to-lymphocyte ratio and calcitonin concentration
for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer.
Mol. Clin. Oncol. 2018, 9, 629–634. [CrossRef]
165. Galdiero, M.R.; Varricchi, G.; Loffredo, S.; Bellevicine, C.; Lansione, T.; Ferrara, A.L.; Iannone, R.; di Somma, S.;
Borriello, F.; Clery, E.; et al. Potential involvement of neutrophils in human thyroid cancer. PLoS ONE
2018, 13, e0199740. [CrossRef]
166. Adrover, J.M.; Nicolas-Avila, J.A.; Hidalgo, A. Aging: A Temporal Dimension for Neutrophils. Trends Immunol.
2016, 37, 334–345. [CrossRef]
167. Silvestre-Roig, C.; Hidalgo, A.; Soehnlein, O. Neutrophil heterogeneity: Implications for homeostasis and
pathogenesis. Blood 2016, 127, 2173–2181. [CrossRef]
168. Sagiv, J.Y.; Michaeli, J.; Assi, S.; Mishalian, I.; Kisos, H.; Levy, L.; Damti, P.; Lumbroso, D.; Polyansky, L.;
Sionov, R.V.; et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer.
Cell Rep. 2015, 10, 562–573. [CrossRef]
169. Groth, C.; Hu, X.; Weber, R.; Fleming, V.; Altevogt, P.; Utikal, J.; Umansky, V. Immunosuppression mediated
by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer. 2019, 120, 16–25.
[CrossRef]
170. Tcyganov, E.; Mastio, J.; Chen, E.; Gabrilovich, D.I. Plasticity of myeloid-derived suppressor cells in cancer.
Curr. Opin. Immunol. 2018, 51, 76–82. [CrossRef]
171. Senovilla, L.; Aranda, F.; Galluzzi, L.; Kroemer, G. Impact of myeloid cells on the efficacy of anticancer
chemotherapy. Curr. Opin. Immunol. 2014, 30, 24–31. [CrossRef]
172. Millrud, C.R.; Bergenfelz, C.; Leandersson, K. On the origin of myeloid-derived suppressor cells. Oncotarget
2017, 8, 3649–3665. [CrossRef]
173. Kumar, V.; Cheng, P.; Condamine, T.; Mony, S.; Languino, L.R.; McCaffrey, J.C.; Hockstein, N.; Guarino, M.;
Masters, G.; Penman, E.; et al. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid
Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity 2016, 44, 303–315. [CrossRef]
174. Condamine, T.; Dominguez, G.A.; Youn, J.I.; Kossenkov, A.V.; Mony, S.; Alicea-Torres, K.; Tcyganov, E.;
Hashimoto, A.; Nefedova, Y.; Lin, C.; et al. Lectin-type oxidized LDL receptor-1 distinguishes population of
human polymorphonuclear myeloid-derived suppressor cells in cancer patients. 2016, 1. [CrossRef]
175. Suzuki, S.; Shibata, M.; Gonda, K.; Kanke, Y.; Ashizawa, M.; Ujiie, D.; Suzushino, S.; Nakano, K.; Fukushima, T.;
Sakurai, K.; et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic
inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol. Clin. Oncol.
2013, 1, 959–964. [CrossRef]
176. Kumar, V.; Patel, S.; Tcyganov, E.; Gabrilovich, D.I. The Nature of Myeloid-Derived Suppressor Cells in the
Tumor Microenvironment. Trends Immunol. 2016, 37, 208–220. [CrossRef]
177. Chiu, D.K.; Tse, A.P.; Xu, I.M.; Di Cui, J.; Lai, R.K.; Li, L.L.; Koh, H.Y.; Tsang, F.H.; Wei, L.L.; Wong, C.M.;
et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through
ENTPD2/CD39L1 in hepatocellular carcinoma. Nat. Commun. 2017, 8, 517. [CrossRef]
178. Cunha, L.L.; Morari, E.C.; Guihen, A.C.; Razolli, D.; Gerhard, R.; Nonogaki, S.; Soares, F.A.; Vassallo, J.;
Ward, L.S. Infiltration of a mixture of immune cells may be related to good prognosis in patients with
differentiated thyroid carcinoma. Clin. Endocrinol. Oxf. 2012, 77, 918–925. [CrossRef]
179. Ohki, S.; Shibata, M.; Gonda, K.; Machida, T.; Shimura, T.; Nakamura, I.; Ohtake, T.; Koyama, Y.; Suzuki, S.;
Ohto, H. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression,
inflammation and hypoproteinemia in patients with cancer. Oncol. Rep. 2012, 28, 453–458. [CrossRef]
180. Angell, T.E.; Lechner, M.G.; Smith, A.M.; Martin, S.E.; Groshen, S.G.; Maceri, D.R.; Singer, P.A.; Epstein, A.L.
Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.
Thyroid 2016, 26, 381–389. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 27 of 31
181. Jolly, L.A.; Massoll, N.; Franco, A.T. Immune Suppression Mediated by Myeloid and Lymphoid Derived
Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by
Hras(G12V) and Pten Loss. J. Clin. Cell Immunol. 2016, 7. [CrossRef]
182. Michelet, X.; Dyck, L.; Hogan, A.; Loftus, R.M.; Duquette, D.; Wei, K.; Beyaz, S.; Tavakkoli, A.; Foley, C.;
Donnelly, R. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses.
Nat. Immunol. 2018, 19, 1330–1340. [CrossRef]
183. Wang, F.; Tian, Z.; Wei, H. Genomic expression profiling of NK cells in health and disease. Eur. J. Immunol.
2015, 45, 661–678. [CrossRef]
184. Modi, J.; Patel, A.; Terrell, R.; Tuttle, R.M.; Francis, G.L. Papillary thyroid carcinomas from young adults and
children contain a mixture of lymphocytes. J. Clin. Endocrinol. Metab. 2003, 88, 4418–4425. [CrossRef]
185. Xu, X.; Rao, G.; Gaffud, M.J.; Ding, H.G.; Maki, G.; Klingemann, H.G.; Groh, V.; Spies, T.; Caillat-Zucman, S.;
Gattuso, P. Clinicopathological significance of major histocompatibility complex class I-related chain a and B
expression in thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91, 2704–2712. [CrossRef]
186. Gogali, F.; Paterakis, G.; Rassidakis, G.Z.; Kaltsas, G.; Liakou, C.I.; Gousis, P.; Neonakis, E.; Manoussakis, M.N.;
Liapi, C. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK
cells in the papillary carcinoma of thyroid. J. Clin. Endocrinol. Metab. 2012, 97, 1474–1482. [CrossRef]
187. Gogali, F.; Paterakis, G.; Rassidakis, G.Z.; Liakou, C.I.; Liapi, C. CD3(-)CD16(-)CD56(bright)
immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with
advanced stages in patients with papillary thyroid cancer. Thyroid 2013, 23, 1561–1568. [CrossRef]
188. Wennerberg, E.; Pfefferle, A.; Ekblad, L.; Yoshimoto, Y.; Kremer, V.; Kaminskyy, V.O.; Juhlin, C.C.; Hoog, A.;
Bodin, I.; Svjatoha, V.; et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated
lysis via ULBP2/5/6 and chemoattract NK cells. Clin. Cancer Res. 2014, 20, 5733–5744. [CrossRef]
189. Azad, P.; Zhao, H.W.; Cabrales, P.J.; Ronen, R.; Zhou, D.; Poulsen, O.; Appenzeller, O.; Hsiao, Y.H.; Bafna, V.;
Haddad, G.G. Senp1 drives hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Monge’s
disease. J. Exp. Med. 2016, 213, 2729–2744. [CrossRef]
190. Park, A.; Lee, Y.; Kim, M.S.; Kang, Y.J.; Park, Y.J.; Jung, H.; Kim, T.D.; Lee, H.G.; Choi, I.; Yoon, S.R.
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression
of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation. Front. Immunol. 2018, 9, 1859. [CrossRef]
191. Yin, M.; Di, G.; Bian, M. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic
thyroid cancer. Int. Immunopharmacol. 2018, 64, 333–339. [CrossRef]
192. Zhu, L.; Li, X.J.; Kalimuthu, S.; Gangadaran, P.; Lee, H.W.; Oh, J.M.; Baek, S.H.; Jeong, S.Y.; Lee, S.W.;
Lee, J.; et al. Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid
Cancer in a Nude Mouse Model. Front. Immunol. 2017, 8, 816. [CrossRef]
193. Crosby, C.M.; Kronenberg, M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol.
2018, 18, 559–574. [CrossRef]
194. Robertson, F.C.; Berzofsky, J.A.; Terabe, M. NKT cell networks in the regulation of tumor immunity.
Front. Immunol. 2014, 5, 543. [CrossRef]
195. Morrow, E.S.; Roseweir, A.; Edwards, J. The role of gamma delta T lymphocytes in breast cancer: A review.
Transl Res. 2019, 203, 88–96. [CrossRef]
196. Ma, Y.; Aymeric, L.; Locher, C.; Mattarollo, S.R.; Delahaye, N.F.; Pereira, P.; Boucontet, L.; Apetoh, L.;
Ghiringhelli, F.; Casares, N.; et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of
anticancer chemotherapy. J. Exp. Med. 2011, 208, 491–503. [CrossRef]
197. Krabbendam, L.; Bal, S.M.; Spits, H.; Golebski, K. New insights into the function, development, and plasticity
of type 2 innate lymphoid cells. Immunol. Rev. 2018, 286, 74–85. [CrossRef]
198. Artis, D.; Spits, H. The biology of innate lymphoid cells. Nature 2015, 517, 293–301. [CrossRef]
199. McHedlidze, T.; Waldner, M.; Zopf, S.; Walker, J.; Rankin, A.L.; Schuchmann, M.; Voehringer, D.;
McKenzie, A.N.; Neurath, M.F.; Pflanz, S.; et al. Interleukin-33-dependent innate lymphoid cells mediate
hepatic fibrosis. Immunity 2013, 39, 357–371. [CrossRef]
200. Crome, S.Q.; Nguyen, L.T.; Lopez-Verges, S.; Yang, S.Y.; Martin, B.; Yam, J.Y.; Johnson, D.J.; Nie, J.;
Pniak, M.; Yen, P.H. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat. Med.
2017, 23, 368–375. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 28 of 31
201. Chevalier, M.F.; Trabanelli, S.; Racle, J.; Salome, B.; Cesson, V.; Gharbi, D.; Bohner, P.; Domingos-Pereira, S.;
Dartiguenave, F.; Fritschi, A.S.; et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder
cancer recurrence. J. Clin. Investig. 2017, 127, 2916–2929. [CrossRef]
202. Russell, J.H.; Ley, T.J. Lymphocyte-mediated cytotoxicity. Ann. Rev. Immunol. 2002, 20, 323–370. [CrossRef]
203. Cunha, L.L.; Marcello, M.A.; Nonogaki, S.; Morari, E.C.; Soares, F.A.; Vassallo, J.; Ward, L.S. CD8+
tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Clin. Endocrinol. Oxf. 2015, 83, 246–253. [CrossRef]
204. Angell, T.E.; Lechner, M.G.; Jang, J.K.; LoPresti, J.S.; Epstein, A.L. MHC class I loss is a frequent mechanism of
immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Clin. Cancer Res. 2014, 20, 6034–6044. [CrossRef]
205. Zhou, Y.; Guo, L.; Sun, H.; Xu, J.; Ba, T. CXCR5+ CD8 T cells displayed higher activation potential despite high
PD-1 expression, in tumor-involved lymph nodes from patients with thyroid cancer. Int. Immunopharmacol.
2018, 62, 114–119. [CrossRef]
206. Quezada, S.A.; Simpson, T.R.; Peggs, K.S.; Merghoub, T.; Vider, J.; Fan, X.; Blasberg, R.; Yagita, H.; Muranski, P.;
Antony, P.A.; et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established
melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207, 637–650. [CrossRef]
207. Ruffell, B.; DeNardo, D.G.; Affara, N.I.; Coussens, L.M. Lymphocytes in cancer development: Polarization
towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21, 3–10. [CrossRef]
208. Speiser, D.E.; Ho, P.C.; Verdeil, G. Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol.
2016, 16, 599–611. [CrossRef]
209. Imam, S.; Paparodis, R.; Sharma, D.; Jaume, J.C. Lymphocytic profiling in thyroid cancer provides clues for
failure of tumor immunity. Endocr. Relat. Cancer 2014, 21, 505–516. [CrossRef]
210. Wolf, D.; Sopper, S.; Pircher, A.; Gastl, G.; Wolf, A.M. Treg(s) in Cancer: Friends or Foe? J. Cell Physiol.
2015, 230, 2598–2605. [CrossRef]
211. French, J.D.; Kotnis, G.R.; Said, S.; Raeburn, C.D.; McIntyre, R.C.; Klopper, J.P., Jr.; Haugen, B.R. Programmed
death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with
aggressive features in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2012, 97, 934–943. [CrossRef]
212. French, J.D.; Weber, Z.J.; Fretwell, D.L.; Said, S.; Klopper, J.P.; Haugen, B.R. Tumor-associated lymphocytes
and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.
J. Clin. Endocrinol Metab. 2010, 95, 2325–2333. [CrossRef]
213. Ryu, H.S.; Park, Y.S.; Park, H.J.; Chung, Y.R.; Yom, C.K.; Ahn, S.H.; Park, Y.J.; Park, S.H.; Park, S.Y. Expression
of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive
features of papillary thyroid microcarcinoma. Thyroid 2014, 24, 1232–1240. [CrossRef]
214. Moretti, S.; Menicali, E.; Nucci, N.; Voce, P.; Colella, R.; Melillo, R.M.; Liotti, F.; Morelli, S.; Fallarino, F.;
Macchiarulo, A.; et al. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3
Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. J. Biol. Chem. 2017, 292, 1785–1797.
[CrossRef]
215. Akdis, M.; Burgler, S.; Crameri, R.; Eiwegger, T.; Fujita, H.; Gomez, E.; Klunker, S.; Meyer, N.; O’Mahony, L.;
Palomares, O.; et al. Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in
diseases. J. Allergy Clin. Immunol. 2011, 127, 701–721. [CrossRef]
216. Johnston, R.J.; Poholek, A.C.; DiToro, D.; Yusuf, I.; Eto, D.; Barnett, B.; Dent, A.L.; Craft, J.; Crotty, S. Bcl6
and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science
2009, 325, 1006–1010. [CrossRef]
217. Vinuesa, C.G.; Linterman, M.A.; Yu, D.; MacLennan, I.C. Follicular Helper T Cells. Ann. Rev. Immunol.
2016, 34, 335–368. [CrossRef]
218. Ueno, H.; Banchereau, J.; Vinuesa, C.G. Pathophysiology of T follicular helper cells in humans and mice.
Nat. Immunol. 2015, 16, 142–152. [CrossRef]
219. Suan, D.; Nguyen, A.; Moran, I.; Bourne, K.; Hermes, J.R.; Arshi, M.; Hampton, H.R.; Tomura, M.; Miwa, Y.;
Kelleher, A.D.; et al. T follicular helper cells have distinct modes of migration and molecular signatures in
naive and memory immune responses. Immunity 2015, 42, 704–718. [CrossRef]
220. Craft, J.E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol.
2012, 8, 337–347. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 29 of 31
221. Zhu, C.; Ma, J.; Liu, Y.; Tong, J.; Tian, J.; Chen, J.; Tang, X.; Xu, H.; Lu, L.; Wang, S. Increased frequency
of follicular helper T cells in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab.
2012, 97, 943–950. [CrossRef]
222. Zhang, J.; Ren, M.; Zeng, H.; Guo, Y.; Zhuang, Z.; Feng, Z.; Yan, H.; Xu, M.; Liang, W.; Yang, C. Elevated
follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of Graves’
disease. Immunol. Res. 2015, 62, 163–174. [CrossRef]
223. Gu-Trantien, C.; Loi, S.; Garaud, S.; Equeter, C.; Libin, M.; de Wind, A.; Ravoet, M.; Le Buanec, H.; Sibille, C.;
Manfouo-Foutsop, G.; et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival.
J. Clin. Investig. 2013, 123, 2873–2892. [CrossRef]
224. Couillault, C.; Germain, C.; Dubois, B.; Kaplon, H. Identification of Tertiary Lymphoid Structure-Associated
Follicular Helper T Cells in Human Tumors and Tissues. Methods Mol. Biol. 2018, 1845, 205–222.
225. Zhao, Y.; Chu, X.; Chen, J.; Wang, Y.; Gao, S.; Jiang, Y.; Zhu, X.; Tan, G.; Zhao, W.; Yi, H.; et al. Dectin-1-activated
dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nat. Commun.
2016, 7, 12368. [CrossRef]
226. Vegran, F.; Berger, H.; Boidot, R.; Mignot, G.; Bruchard, M.; Dosset, M.; Chalmin, F.; Rebe, C.; Derangere, V.;
Ryffel, B.; et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.
Nat. Immunol. 2014, 15, 758–766. [CrossRef]
227. Lu, Y.; Wang, Q.; Xue, G.; Bi, E.; Ma, X.; Wang, A.; Qian, J.; Dong, C.; Yi, Q. Th9 Cells Represent a Unique Subset
of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell. 2018, 33, 1048–1060.
[CrossRef]
228. Brauner, E.; Gunda, V.; Vanden Borre, P.; Zurakowski, D.; Kim, Y.S.; Dennett, K.V.; Amin, S.; Freeman, G.J.;
Parangi, S. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression
and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget
2016, 7, 17194–17211. [CrossRef]
229. Gunda, V.; Gigliotti, B.; Ashry, T.; Ndishabandi, D.; McCarthy, M.; Zhou, Z.; Amin, S.; Lee, K.E.; Stork, T.;
Wirth, L.; et al. Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune
microenvironment of murine anaplastic thyroid cancer. Int. J. Cancer 2018, 144, 2266–2278. [CrossRef]
230. Varricchi, G.; Galdiero, M.R.; Tocchetti, C.G. Cardiac Toxicity of Immune Checkpoint Inhibitors:
Cardio-Oncology Meets Immunology. Circulation 2017, 136, 1989–1992. [CrossRef]
231. Tocchetti, C.G.; Galdiero, M.R.; Varricchi, G. Cardiac Toxicity in Patients Treated with Immune Checkpoint
Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. J. Am. Coll. Cardiol. 2018, 71, 1765–1767. [CrossRef]
232. Varricchi, G.; Galdiero, M.R.; Mercurio, V.; Bonaduce, D.; Marone, G.; Tocchetti, C.G. Pharmacovigilating
cardiotoxicity of immune checkpoint inhibitors. Lancet Oncol. 2018, 19, 1545–1546. [CrossRef]
233. Fritz, J.M.; Lenardo, M.J. Development of immune checkpoint therapy for cancer. J. Exp. Med.
2019, 216, 1244–1254. [CrossRef]
234. Okazaki, T.; Chikuma, S.; Iwai, Y.; Fagarasan, S.; Honjo, T. A rheostat for immune responses: The unique
properties of PD-1 and their advantages for clinical application. Nat. Immunol. 2013, 14, 1212–1218.
[CrossRef]
235. Kataoka, K.; Shiraishi, Y.; Takeda, Y.; Sakata, S.; Matsumoto, M.; Nagano, S.; Maeda, T.; Nagata, Y.;
Kitanaka, A.; Mizuno, S.; et al. Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers.
Nature 2016, 534, 402–406. [CrossRef]
236. Peggs, K.S.; Quezada, S.A.; Chambers, C.A.; Korman, A.J.; Allison, J.P. Blockade of CTLA-4 on both
effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
J. Exp. Med. 2009, 206, 1717–1725. [CrossRef]
237. Bastman, J.J.; Serracino, H.S.; Zhu, Y.; Koenig, M.R.; Mateescu, V.; Sams, S.B.; Davies, K.D.; Raeburn, C.D.;
McIntyre, R.C.; Haugen, B.R., Jr.; et al. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in
Advanced Differentiated and Anaplastic Thyroid Cancer. J. Clin. Endocrinol. Metab. 2016, 101, 2863–2873.
[CrossRef]
238. Chintakuntlawar, A.V.; Rumilla, K.M.; Smith, C.Y.; Jenkins, S.M.; Foote, R.L.; Kasperbauer, J.L.; Morris, J.C.;
Ryder, M.; Alsidawi, S.; Hilger, C. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients
Treated with Multimodal Therapy: Results From a Retrospective Study. J. Clin. Endocrinol. Metab.
2017, 102, 1943–1950. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 30 of 31
239. Colli, L.M.; Machiela, M.J.; Myers, T.A.; Jessop, L.; Yu, K.; Chanock, S.J. Burden of Nonsynonymous
Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res.
2016, 76, 3767–3772. [CrossRef]
240. Mehnert, J.M.; Varga, A.; Brose, M.S.; Aggarwal, R.R.; Lin, C.C.; Prawira, A.; de Braud, F.; Tamura, K.; Doi, T.;
Piha-Paul, S.A.; et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients
with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 2019, 19, 196. [CrossRef]
241. Gunda, V.; Gigliotti, B.; Ndishabandi, D.; Ashry, T.; McCarthy, M.; Zhou, Z.; Amin, S.; Freeman, G.J.;
Alessandrini, A.; Parangi, S. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve
survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid
cancer. Br. J. Cancer 2018, 119, 1223–1232. [CrossRef]
242. Iyer, P.C.; Dadu, R.; Gule-Monroe, M.; Busaidy, N.L.; Ferrarotto, R.; Habra, M.A.; Zafereo, M.; Williams, M.D.;
Gunn, G.B.; Grosu, H.; et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of
anaplastic thyroid carcinoma. J. Immunother. Cancer 2018, 6, 68. [CrossRef]
243. Waterhouse, P.; Penninger, J.M.; Timms, E.; Wakeham, A.; Shahinian, A.; Lee, K.P.; Thompson, C.B.;
Griesser, H.; Mak, T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science
1995, 270, 985–988. [CrossRef]
244. Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like autoimmune diseases by
disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11, 141–151.
[CrossRef]
245. Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.;
Hiai, H.; Minato, N.; et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science
2001, 291, 319–322. [CrossRef]
246. Vaidya, B.; Pearce, S.H.; Charlton, S.; Marshall, N.; Rowan, A.D.; Griffiths, I.D.; Kendall-Taylor, P.;
Cawston, T.E.; Young-Min, S. An association between the CTLA4 exon 1 polymorphism and early rheumatoid
arthritis with autoimmune endocrinopathies. Rheumatology 2002, 41, 180–183. [CrossRef]
247. Hudson, L.L.; Rocca, K.; Song, Y.W.; Pandey, J.P. CTLA-4 gene polymorphisms in systemic lupus
erythematosus: A highly significant association with a determinant in the promoter region. Hum. Genet.
2002, 111, 452–455. [CrossRef]
248. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Snook, H.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.;
Smith, A.N.; Di Genova, G.; et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to
autoimmune disease. Nature 2003, 423, 506–511. [CrossRef]
249. Blomhoff, A.; Lie, B.A.; Myhre, A.G.; Kemp, E.H.; Weetman, A.P.; Akselsen, H.E.; Huseby, E.S.; Undlien, D.E.
Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison’s
disease. J. Clin. Endocrinol. Metab. 2004, 89, 3474–3476. [CrossRef]
250. Zhernakova, A.; Eerligh, P.; Barrera, P.; Wesoly, J.Z.; Huizinga, T.W.; Roep, B.O.; Wijmenga, C.; Koeleman, B.P.
CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum. Genet.
2005, 118, 58–66. [CrossRef]
251. Fernandez-Mestre, M.; Sanchez, K.; Balbas, O.; Gendzekhzadze, K.; Ogando, V.; Cabrera, M.; Layrisse, Z. Influence
of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum. Immunol. 2009, 70, 532–535.
[CrossRef]
252. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.;
Lotem, M.; et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015, 372, 2521–2532.
[CrossRef]
253. Weber, J.S.; D’Angelo, S.P.; Minor, D.; Hodi, F.S.; Gutzmer, R.; Neyns, B.; Hoeller, C.; Khushalani, N.I.;
Miller, W.H.; Lao, C.D., Jr.; et al. Nivolumab versus chemotherapy in patients with advanced melanoma who
progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3
trial. Lancet Oncol. 2015, 16, 375–384. [CrossRef]
254. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.;
Smylie, M.; Rutkowski, P.; et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated
Melanoma. N. Engl. J. Med. 2015, 373, 23–34. [CrossRef]
255. De Filette, J.; Jansen, Y.; Schreuer, M.; Everaert, H.; Velkeniers, B.; Neyns, B.; Bravenboer, B. Incidence of
Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J. Clin. Endocrinol. Metab.
2016, 101, 4431–4439. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 3934 31 of 31
256. Delivanis, D.A.; Gustafson, M.P.; Bornschlegl, S.; Merten, M.M.; Kottschade, L.; Withers, S.; Dietz, A.B.;
Ryder, M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying
Involved Mechanisms. J. Clin. Endocrinol. Metab. 2017, 102, 2770–2780. [CrossRef]
257. Byun, D.J.; Wolchok, J.D.; Rosenberg, L.M.; Girotra, M. Cancer immunotherapy-immune checkpoint blockade
and associated endocrinopathies. Nat. Rev. Endocrinol. 2017, 13, 195–207. [CrossRef]
258. Alhusseini, M.; Samantray, J. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with
anti-PD1 Agents: Insights on Underlying Mechanisms. Exp. Clin. Endocrinol. Diabetes. 2017, 125, 267–269.
[CrossRef]
259. Eggermont, A.M.; Chiarion-Sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.;
Robert, C.; Ascierto, P.A.; Richards, J.M.; et al. Adjuvant ipilimumab versus placebo after complete resection
of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol.
2015, 16, 522–530. [CrossRef]
260. Ferrari, S.M.; Fallahi, P.; Galetta, F.; Citi, E.; Benvenga, S.; Antonelli, A. Thyroid disorders induced by
checkpoint inhibitors. Rev. Endocr. Metab. Disord. 2018, 19, 325–333. [CrossRef]
261. Antonelli, A.; Ferrari, S.M.; Fallahi, P. Current and future immunotherapies for thyroid cancer. Expert Rev.
Anticancer Ther. 2018, 18, 149–159. [CrossRef]
262. Ferrari, S.M.; Fallahi, P.; Politti, U.; Materazzi, G.; Baldini, E.; Ulisse, S.; Miccoli, P.; Antonelli, A. Molecular
Targeted Therapies of Aggressive Thyroid Cancer. Front. Endocrinol. Lausanne 2015, 6, 176. [CrossRef]
263. Atkins, M.B.; Larkin, J. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of
Solid Tumors: Current Perspectives. J. Natl. Cancer Inst. 2016, 108, 414. [CrossRef]
264. Palmer, A.C.; Sorger, P.K. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability
without Drug Additivity or Synergy. Cell 2017, 171, 1678–1691. [CrossRef]
265. Lee, C.S.; Cragg, M.; Glennie, M.; Johnson, P. Novel antibodies targeting immune regulatory checkpoints for
cancer therapy. Br. J. Clin. Pharmacol. 2013, 76, 233–247. [CrossRef]
266. Khan, K.A.; Kerbel, R.S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice
versa. Nat. Rev. Clin. Oncol. 2018, 15, 310–324. [CrossRef]
267. Nguyen, L.T.; Ohashi, P.S. Clinical blockade of PD1 and LAG3–potential mechanisms of action.
Nat. Rev. Immunol. 2015, 15, 45–56. [CrossRef]
268. Russell, S.J.; Peng, K.W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30, 658–670. [CrossRef]
269. Passaro, C.; Borriello, F.; Vastolo, V.; Di Somma, S.; Scamardella, E.; Gigantino, V.; Franco, R.; Marone, G.;
Portella, G. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs
angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 2016, 7, 1500–1515.
[CrossRef]
270. Martinez-Quintanilla, J.; Seah, I.; Chua, M.; Shah, K. Oncolytic viruses: Overcoming translational challenges.
J. Clin. Investig. 2019, 130. [CrossRef]
271. Kirschner, L.S.; Qamri, Z.; Kari, S.; Ashtekar, A. Mouse models of thyroid cancer: A 2015 update.
Mol. Cell Endocrinol. 2016, 421, 18–27. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
